Richard J. Settles, D.O.; Decision and Order, 64940-64949 [2016-22680]
Download as PDF
64940
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
Order
Pursuant to the authority vested in me
by 21 U.S.C. § 824(a), as well as 28 CFR
0.100(b), I order that DEA Certificate of
Registration AS3236406, issued to
Charles Szyman, D.O., be, and it hereby
is, revoked. This Order is effective
immediately.4
Dated: September 13, 2016.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2016–22677 Filed 9–20–16; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK3G9T082PROD with NOTICES
Richard J. Settles, D.O.; Decision and
Order
On September 9, 2015, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Richard J. Settles, D.O.
(hereinafter, Respondent), of Grand
Junction, Colorado. The Show Cause
Order proposed the revocation of
Respondent’s DEA Certificate of
Registration FS3717975, pursuant to
which he is authorized to dispense
controlled substances in schedules II
through V, as a practitioner, at the
registered address of 715 Horizon Drive,
Suite 200, Grand Junction, Colorado. GX
2, at 1 (citing 21 U.S.C. 824(a)(1) and
(4)). The Show Cause Order also
proposed the denial of any pending
application to renew or modify
Respondent’s registration, on the ground
that his ‘‘continued registration is
inconsistent with the public interest.’’
Id.
As grounds for the proposed actions,
the Government alleged that
Respondent had materially falsified his
March 4, 2013 application for
registration. Id. at 2 (21 U.S.C.
824(a)(1)). The Order also alleged that
he had issued prescriptions for
controlled substances without authority
to do so under both Arizona and Federal
law. Id. at 3 (citing 21 U.S.C. 824(a)(4)).
With respect to the material
falsification allegation, the Government
alleged that on March 4, 2013,
Respondent applied for a DEA
registration at a location in Chattanooga,
Tennessee. Id. at 1. The Government
alleged that Respondent provided a
‘‘yes’’ answer to the application
4 For the same reasons which led the Wisconsin
Board to summarily suspend Respondent’s
osteopathic license, see supra note 2, I find that the
public interest necessitates that this Order be
effective immediately. 21 CFR 1316.67.
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
question: ‘‘Has the applicant ever
surrendered (for cause) or had a state
professional license or controlled
substances registration revoked,
suspended, restricted, or placed on
probation, or is any such action
pending?’’ and that ‘‘[i]n furtherance of
[his] answer,’’ Respondent explained
that on July 17, 2012, ‘‘the Arizona
Board of Osteopathic Examiners placed
my license on a 5 year probation,’’ and
that as a result, ‘‘I voluntarily
surrendered my Arizona license and
DEA registration as I knew I was moving
to Tennessee in the next few months.’’
Id. at 1–2.
The Government then alleged that
Respondent’s answer was materially
false because he was ‘‘aware of at least
two . . . other state professional license
actions’’ when he submitted the
application and failed to disclose them.
Id. at 2. The Government alleged that
these actions included a November 17,
2012 Interim Consent Order issued by
the Arizona Board, which restricted
Respondent’s license to practice
osteopathic medicine pending the
Board’s investigation into whether he
violated its July 17, 2012 Order by
prescribing controlled substances as his
authority to do so had been restricted by
that Order. Id. As for the second Board
action, the Government alleged that on
February 6, 2013, Respondent entered
into a Stipulation and Order with the
Utah Division of Occupational and
Professional Licensing, in which he
admitted that he had falsified a May 4,
2012 application for licensure in that
State, because he failed to disclose that
he was then under investigation by the
Arizona Board, and that he had
surrendered his Utah license to practice
as an osteopath. Id. at 2–3 (citing 21
U.S.C. 824(a)(1), 823(f), 843(a)(4)(A)).
As for the prescribing allegations, the
Government alleged that pursuant to the
July 17, 2012 Arizona Board Order,
Respondent was restricted from
prescribing schedule I through IV
controlled substances. Id. at 3. The
Order alleged that the Board
subsequently found that after the
effective date of the Order, Respondent
became the medical director of a
hospice program and prescribed
controlled substances to 10 of the
program’s patients. Id. The Order then
alleged that ‘‘[p]rescribing controlled
substances without appropriate
authority is contrary to Federal law.’’ Id.
at 3 (citations omitted).
Next, the Order alleged that on May
7, 2014, one day before the Tennessee
State Board of Osteopathic Examination
issued a Consent Order which
indefinitely suspended his Tennessee
license, Respondent applied to modify
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
his registered address from Tennessee to
an address in Dolores, Colorado. Id. at
4. The Order alleged that Respondent
made several additional requests to
modify his registered address,
concluding with his February 18, 2015
request to change his address to a
location in Grand Junction, Colorado
and that the Agency approved this
request on March 17, 2015. Id.
The Order then alleged that prior to
the Agency’s approval of his
modification request, Respondent
issued controlled substance
prescriptions in Colorado, ‘‘in violation
of 21 U.S.C. 810(10),1 822(e), and
841(a)(1).’’ Id. at 4 (citing, inter alia, 21
CFR 1301.12(a), 1301.13(a)).
Specifically, the Order alleged that
‘‘from July 2014 through February 2015,
[Respondent] issued over 250
prescriptions when [he] lacked the
requisite federal authority to issue
prescriptions in Colorado.’’ Id. The
Order then set forth multiple instances
of such prescriptions. Id. at 5–6. The
Order further alleged that Respondent
‘‘issued multiple prescriptions to
patients within a thirty-day window,
amounting to prescriptions for large
dosages of highly abused controlled
substances’’ and set forth a dozen
patients to whom he issued the
prescriptions. Id. at 6–7.
On September 14, 2015, the Show
Cause Order, which also notified
Respondent of his right to request a
hearing on the allegations or to submit
a written statement in lieu of a hearing,
the procedure for electing either option,
and the consequence for failing to elect
either option, was served on
Respondent by certified mail, return
receipt requested. GX 4, at 1. Thereafter,
on October 14, 2015, Respondent,
through his attorney, filed a document
entitled ‘‘Waiver of Hearing, Statement
of Position on the Facts and Law’’
(hereinafter ‘‘Position Statement’’) with
the Office of Administrative Law Judges.
See 21 CFR 1301.43(c); GX 5. Therein,
Respondent acknowledged service of
the Order to Show Cause on September
14, 2015, see GX 5 at 5, and explained
he was waiving his right to a hearing
and filing his ‘‘Statement of Position on
the Facts and Law regarding the matters
alleged in the Order to Show Cause.’’
GX 5, at 2.
On February 29, 2016, the
Government forwarded its Request for
Final Agency action, the Investigative
Record, and Respondent’s Position
Statement. Subsequently, on March 21,
2016, the Government filed an
Addendum to its Request for Final
Agency Action (hereinafter, First
1 There
E:\FR\FM\21SEN1.SGM
is no such provision in the CSA.
21SEN1
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
Addendum). Therein, the Government
notified my Office that Respondent did
not file his renewal application until
February 2, 2106,2 which was less than
45 days before the expiration date of his
registration (Feb. 29, 2016). Noting that
under an agency regulation, ‘‘‘a
registrant, who has been served with an
Order to Show Cause, [must] file his
renewal application at least 45 days
before the expiration of his registration,
in order for it to continue in effect past
its expiration date and pending the
issuance of a final order,’’’ and that
Respondent had filed his renewal
application less than 45 days prior to
the expiration of his registration, the
Government argued that Respondent’s
registration had expired and thus, ‘‘the
issue to be considered . . . is whether
DEA should grant [his] application . . .
not whether DEA should revoke
Respondent’s registration.’’ Id. at 1
(quoting Paul Weir Battershell, 76 FR
44359, 44361 (2011) (quoting 21 CFR
1301.36(i))).
On April 28, 2016 the Government
filed a second Addendum to its Request
for Final Agency Action (hereinafter,
Second Addendum). Therein, the
Government advised that ‘‘the Medical
Board of Colorado issued an Order of
Suspension which suspended
Applicant’s Colorado medical license,
effective Friday, April 22, 2016’’; the
Government provided a copy of the
Board’s Order.3 Id. at 1; see also
Attachment (GX 27), at 1–2. The Board’s
Order has been made a part of the
Investigative Record in this proceeding.
mstockstill on DSK3G9T082PROD with NOTICES
Respondent’s Position Statement
Respondent’s Position Statement
raises various contentions which
warrant discussion prior to my
determination of the material facts in
this matter. As a preliminary matter,
Respondent asserts that ‘‘in waiving his
right to participate in the hearing[,] [he]
did not and does not waive any rights
other than his right to a hearing’’ and
that ‘‘there is no authority in the
regulations of the Agency to waive any
other rights pertaining to the
adjudication of this matter.’’ GX 5, at 1.
Among other things, Respondent
contends that the Administrative Law
Judge is required, ‘‘upon receipt of a
waiver of hearing and statement on the
2 On the date the Show Cause Order was issued,
Respondent was registered as a practitioner to
handle controlled substances in schedules II–V
under DEA Registration FS3717975 at the registered
address of La Junta Clinic, 715 Horizon Drive, Suite
200, Grand Junction, Colorado; this registration,
which was issued on March 5, 2013, was due to
expire by its terms on February 29, 2016. GX 1.
3 The Government certified that a copy of both
Addendums was served on Respondent’s counsel.
First Addendum, at 3; Second Addendum at 2.
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
matters of fact and law to determine if
the statement is admissible, and if so
make the statement part of the record.’’
Id. at 3 (citing 21 CFR 1316.49).
Respondent then argues that he ‘‘is
entitled to have the ALJ certify the
record in this proceeding to the
Administrator,’’ that ‘‘the ALJ’s
jurisdiction . . . does not terminate
until after he certifies the record,’’ that
‘‘a termination of the proceedings that
permits the Government’s counsel to
determine what constitutes the record is
a clear violation of this regulation,’’ and
that ‘‘[t]he ALJ’s role and authority is
not altered by the waiver of a hearing.’’
Id. at 4 (citing 21 CFR 1316.52).
Respondent is mistaken. Under the
Agency’s rules, absent the filing of a
request for a hearing on an Order to
Show Cause, the Office of
Administrative Law Judges does not
acquire jurisdiction over the matter.
Here, Respondent did not file a request
for a hearing, and indeed, explicitly
waived his right to a hearing.
Accordingly, no Administrative Law
Judge was designated as a presiding
officer and because no hearing was held,
there was no record to be certified by a
member of the Office of Administrative
Law Judges.
Thus, the Government, while it was
required to submit Respondent’s
Position Statement with its filing, was
otherwise entitled to determine what
evidence it would submit to my Office
in support of its Request for Final
Agency action. Moreover, the
Government has represented to me that
it provided to Respondent a copy of its
Request for Final Agency Action, the
Exhibits, the Addendums, and the
Attachment to the Second Addendum.
Accordingly, as the Government has
provided Respondent with all of its
filings, Respondent cannot claim that it
has been stripped ‘‘of its status as a
party to the proceeding.’’ 4 Id. For the
same reason, I reject Respondent’s
assertion that a ‘‘quagmire . . . would
ensue if the proceedings were cancelled
in their entirety 5 and Government
Counsel were permitted to seek a final
order by presenting DEA’s case directly
4 As support for this contention, Respondent
quotes 20 CFR 404.929, a regulation applicable to
certain hearings conducted by ALJs on behalf of the
Social Security Administration. See GX 5, at 4. This
provision has no relevance to this proceeding.
5 Respondent offers no explanation as to what
further rights he believes he is entitled to, given that
he has waived his right to a hearing and has filed
his Position Statement. Nor does he explain what
he believes remains of the proceeding other than
the Government’s submission of its Request for
Final Agency Action and its evidence and my
issuance of this Decision and Order.
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
64941
to the Administrator in ex parte
communications.’’ Id. at 5.
Respondent further argues that under
21 CFR 1301.43(c), I ‘‘may not terminate
the proceeding and issue [my] final
order unless ‘all persons entitled to a
hearing or to participate in a hearing
waive . . . their opportunity for the
hearing or to participate in the hearing.’’
Id. (quoting 21 CFR 1301.43(e)) 6
(emphasis in Respondent’s Position
Statement). Respondent then argues that
‘‘DEA is entitled to participate in the
hearing and . . . has counsel of record
representing it,’’ but ‘‘has not waived its
opportunity to participate in the
hearing.’’ Id. at 4. Respondent thus
contends that ‘‘canceling the hearing
and allowing the Administrator to issue
[his] final order is not authorized.’’ Id.
Once again, Respondent is mistaken.
Notwithstanding that an agency
regulation applicable to hearings (21
CFR 1316.42(e)) defines the ‘‘[t]he term
person [to] include[] an individual,
corporation, government or
governmental subdivision or agency,’’
when the Government initiates an Order
to Show Cause proceeding, it is not a
‘‘person entitled to a hearing’’ within
the meaning of 21 CFR 1301.43.7
Indeed, this language is fairly read as
encompassing only the recipient of the
Show Cause Order.
For the same reason, i.e., because it
initiated the proceeding, when the
Government initiates an Order to Show
Cause proceeding, it is not a ‘‘person
entitled to participate in a hearing
pursuant to § 1301.34 or § 1301.35(b).’’
21 CFR 1301.43(b). With respect to
§ 1301.34, this provision applies to only
a narrow category of cases which are not
initiated by the Government—
specifically, where an applicant seeks
registration to import schedule I or II
controlled substances. Under this
provision, the Agency is required to give
notice to registered manufacturers as
6 The
correct regulation is 21 CFR 1301.43(e).
take their meaning from the context in
which they are used, and in this regard the language
of 21 CFR 1301.43(a) is probative. It states: ‘‘Any
person entitled to a hearing pursuant to § 1301.32
or §§ 1301.34–1301.36 and desiring a hearing shall,
within 30 days after the date of receipt of the order
to show cause . . . file with the Administrator a
written request for a hearing in the form prescribed
in § 1316.47 of this chapter.’’ The reference
provisions apply to applicants for registration
whose applications the Agency is proposing to
deny, and the holders of registrations whose
registrations the Agency is proposing to revoke. As
the provision applicable to Respondent states:
‘‘[b]efore revoking or suspending any registration,
the Administrator shall issue an order to show
cause pursuant to § 1301.37 and, if requested by the
registrant, shall hold a hearing pursuant to
§ 1301.41.’’ 21 CFR 1301.36(d) (emphasis added).
Here, however, Respondent did not request a
hearing but rather chose to submit a position
statement in lieu thereof.
7 Words
E:\FR\FM\21SEN1.SGM
21SEN1
64942
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
well as other applicants for registration
to manufacturer the same basic
substance, and upon request of such
manufacturer or applicant, the Agency
‘‘shall hold a hearing on the
application.’’ 21 CFR 1301.34(a). While
Government does not initiate the
proceeding, it may intervene in the
proceeding as a ‘‘person entitled to
participate in a hearing.’’ 21 CFR
1301.43(b). See also e.g., Chattem
Chemicals, Inc., 71 FR 9834, 9834
(2006), pet. for rev. denied sub nom.
Penick Corp, Inc., v. DEA, 491 F.3d 483,
493 (D.C. Cir. 2007); Penick Corp., Inc.,
68 FR 6947, 6947 (2003), pet. for rev.
denied sub nom. Noramco, Inc., v. DEA,
375 F.3d 1148, 1159 (D.C. Cir. 2004).
Indeed, this is the only circumstance in
which the Government can be fairly
described as a ‘‘person entitled to
participate in a hearing.’’ 8
Thus, with respect to this proceeding,
the Government is neither a ‘‘person[]
entitled to a hearing or to participate in
a hearing,’’ 21 CFR 1301.43(e), and the
only person whose waiver matters for
the purpose of cancelling the hearing is
Respondent. Because Respondent has
waived his right to a hearing, I am
authorized to issue this ‘‘final order . . .
without a hearing.’’ 9 Id.
Having reviewed the entire record,
including Respondent’s Statement of
Position, I make the following factual
findings.
FINDINGS OF FACT
mstockstill on DSK3G9T082PROD with NOTICES
Jurisdictional Facts
Respondent, a doctor of osteopathic
medicine, previously held DEA
Certificate of Registration FS3717975,
pursuant to which he was authorized to
dispense controlled substances in
schedules II–V, at the address of La
Junta Clinic, 1012 Belmont Ave., La
Junta, Colorado. GX 1. This registration
was issued on March 5, 2013, after
Respondent submitted the application
8 21 CFR 1301.43(b) also refers to the provisions
of 1301.35(b), which allow for registered bulk
manufacturers of a basic substance in schedule I or
II (as well as applicants for registration to
manufacture the basis substance) to ‘‘participate in
a hearing’’ when the Government has issued a Show
Cause Order proposing the denial of an application
for registration ‘‘to manufacture in bulk’’ the same
basic class and the applicant has requested a
hearing. Here too, the Government is not a ‘‘person
entitled to participate in a hearing.’’ Rather, it is
initiator of the proceeding.
9 The Agency’s longstanding and consistent
practice is that where a party waives its right to a
hearing, the Government is entitled to present its
evidence directly to the Administrator, who is the
ultimate factfinder. See, e.g., Cf. Reckitt & Colman,
Ltd. v. Administrator, 788 F.2d 22, 26 (quoting 5
U.S.C. 557(b) (‘‘On appeal from or review of the
initial decision, the agency has all the powers
which it would have in making the initial decision
. . . .’’)). This practice has been followed in
hundreds of cases over the years.
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
which is the subject of the material
falsification allegations. On February 2,
2016, Respondent submitted an
application to renew this registration.
First Addendum, at 1. However, because
Respondent had previously been served
with the Show Cause Order, in order for
his registration to remain valid pending
this proceeding, he was required to
submit his application at least 45 days
before the date on which the registration
was due to expire. 21 CFR 1301.36(i).
Accordingly, I find that Respondent’s
registration expired on February 29,
2016. I further find, however, that
Respondent’s application remains
pending in this proceeding.10
The Arizona and Utah Investigations of
Respondent
On April 29, 2010, the mother of
Respondent’s patient K.K. made a
complaint to the Arizona Board of
Osteopathic Examiners alleging that
K.K. was a heroin addict and that
Respondent was prescribing drugs and
quantities that ‘‘were inappropriate
[given] K.K.’s history with substance
abuse.’’ GX 8, at 2. The same day, the
Board notified Respondent that it was
initiating an investigation. Id. at 1.
Thereafter, Respondent was invited to
attend an investigative hearing which
was conducted on September 24, 2011;
the hearing was continued to allow the
Board to obtain additional information
and conduct ‘‘a chart review of thirty
(30) patients.’’ Id. The Board also
ordered Respondent to undergo a
psychological evaluation and requested
that he provide additional
documentation to it. Id.
On April 10, 2012, the Board notified
Respondent ‘‘that the Investigative
Hearing would continue on May 19,
2012.’’ Id. On that date, the Board
conducted the hearing with Respondent
present and represented by counsel. Id.
Thereafter, the Board issued a decision
and order which made factual findings
and legal conclusions regarding
Respondent’s prescribing to K.K. as well
as its chart review.
With respect to K.K., the Board found
that she was Respondent’s patient ‘‘from
March 2005 through March 2010, with
10 Respondent previously held DEA Certificate of
Registration BS3176105. GX 7, at 3. Pursuant to this
registration, Respondent was authorized to dispense
controlled substances in schedules II through V, at
the registered location of 10752 North 89th Place,
Suite 218, Scottsdale, Arizona 85620. GX 9, at 1.
However, on July 30, 2012, Respondent surrendered
this registration ‘‘[i]n view of [his] alleged failure to
comply with the Federal requirements pertaining to
controlled substances, and as an indication of my
good faith in desiring to remedy any incorrect or
unlawful practice on [his] part.’’ Id. This
registration was retired the following day. GX 7, at
3.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
a lapse in care from February 2006 to
early 2009.’’ Id. at 2. The Board found
that at K.K.’s second visit, Respondent
prescribed Percocet to her in quantities
ranging from 120 to 180 dosage units
each month as well as 90 Xanax and 30
Ambien each month. Id. The Board
further found that ‘‘Respondent failed to
obtain prior medical records or to
perform a workup on K.K. and no
consultations were ordered.’’ Id. It also
found that ‘‘[t]he majority of K.K.’s
medications were obtained through
Respondent’s office’’ and that he ‘‘did
not enter into a medication contract
with [her] until May 5, 2010 for
Suboxone.’’ Id.
Continuing, the Board found that K.K.
‘‘returned to Respondent . . . in 2009
and . . . was started on’’ 90 Percocet
and 90 Soma, and that ‘‘[i]n October
2009, K.K. overdosed and was taken to
the hospital.’’ Id. The Board found that
‘‘Respondent continued’’ to provided
K.K. with prescriptions each month for
120 dosage units of Percocet, 90 Xanax,
and 30 Ambien until March 2010, when
he increased her Percocet prescription
to 180 du per month. Id. According to
the Board, K.K. overdosed again on
March 17, 2010 as well as on April 11,
2010. Id. at 2–3.
With respect to the chart review, the
Board found that ‘‘Respondent
prescribed controlled substances to
chronic pain patients’’ and that
‘‘[p]harmacy inquiries and drug screens
were ignored in patients that were
clearly diverting.’’ Id. at 3. The Board
further found that ‘‘Respondent
deviated from the standard of care by
failing to’’:
(1) ‘‘stop prescribing controlled substances
for patients that had overdosed’’;
(2) ‘‘recognize drug seeking behavior in
patients’’;
(3) ‘‘request prior medical records’’;
(4) ‘‘obtain appropriate laboratory testing’’;
(5) ‘‘conduct a physical exam in at least
one patient’’;
(6) ‘‘obtain consultations’’; and
(7) ‘‘follow the directions of specialist [sic]
or recommendations when consultations
were obtained.’’
Id.
The Board thus found that
‘‘Respondent practice[d] medicine in a
manner that harmed or had potential to
harm patients and fell below the
community standard . . . and . . . this
conduct endangered a patient or the
public’s health.’’ Id. And the Board
concluded that Respondent engaged in
unprofessional conduct by ‘‘ ‘[e]ngaging
in the practice of medicine in a manner
that harms or may harm a patient or that
the board determines falls below the
community,’ ’’ as well as that he
engaged in ‘‘ ‘[a]ny conduct or practice
E:\FR\FM\21SEN1.SGM
21SEN1
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
that endangers the public’s health or
may reasonably be expected to do so.’’’
Id. at 4 (quoting Ariz. Rev. Stat. §§ 32–
1854(6) & (38)).
Based on the above, the Board
censured Respondent and ‘‘restricted’’
him ‘‘from prescribing or recommending
Schedule I, II, III or IV controlled
substances for a period of two years . . .
from’’ the Order’s effective date. The
Board also restricted him from
practicing pain management, imposed a
civil penalty of $1,000 and placed him
on probation for a period of five years,
the terms of which included that he
‘‘obey all federal, state and local laws,
and rules governing the practice of
medicine in the State of Arizona.’’ Id.
The Order became effective on July 17,
2012. GX 10, at 3.
As found above, on July 30, 2012,
Respondent voluntarily surrendered his
then DEA registration (BS3176105).
Thereafter, on October 12, 2012, the
Board received information form
anonymous sources that Respondent
‘‘may be prescribing controlled
substances.’’ GX 16, at 1. In response,
the Board queried the Board of
Pharmacy’s Controlled Substances
Prescription Monitoring Program ‘‘for
all controlled substances written or
ordered by [Respondent] from June 11,
2012 through October 15, 2012.’’ Id. The
query showed that between July 17,
2012 and October 15, 2012, Respondent
had issued 99 prescriptions for schedule
II drugs, 23 prescriptions for schedule
III drugs, and 70 prescriptions for
schedule IV drugs. Id. at 1–2. The Board
identified one patient Respondent saw
at his office who received a prescription
for temazepam on August 21, 2012, and
11 patients at hospices in Tuscon and
Mesa to whom he either prescribed or
ordered the dispensing of controlled
substances, which included morphine,
hydromorphone, oxycodone, lorazepam
and temazepam. Id. at 2–6. Moreover,
Respondent issued 17 controlled
substance prescriptions or orders for the
dispensing of controlled substances for
12 patients after he surrendered his DEA
registration. Id.
On November 9, 2012, Respondent
was interviewed by the Board and
admitted ‘‘that he had signed
prescriptions for Schedule I, II, III or IV
controlled substances after the Effective
Date’’ of the Order. GX 10, at 4.
Respondent denied having ‘‘written
prescriptions for patients in his private
practice’’ and ‘‘stated that he had only
written or authorized prescriptions in
his capacity as the . . . medical director
for various hospice locations.’’ 11 Id.
11 Under the probationary terms of the July 17,
2012 Order, Respondent was required to hire a
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
On November 16, 2012, Respondent
entered into an Interim Consent
Agreement which the Board approved
the following day. Id. at 2, 5.
Respondent admitted to the findings of
fact contained therein, including that he
had prescribed or ordered controlled
substances after the July 17, 2012 Order
became effective, as well as the legal
conclusion that he had engaged in
unprofessional conduct by ‘‘[v]iolating a
formal order, probation or a stipulation
issued by the board.’’ Id. at 1, 4. The
Board then ordered that Respondent be
‘‘restricted from practicing medicine
until the investigation’’ was completed
and ‘‘he appear[ed] before the Board
. . . for resolution’’ of the matter. Id. at
4.
On May 12, 2014, Respondent entered
into a Consent Agreement and Order for
Voluntary Surrender of Licensee. GX 12,
at 1, 5. Therein, Respondent waived his
right to a hearing before the Board. Id.
at 2. The Board found, inter alia, that on
August 1, 2012, Respondent had
‘‘entered into an Independent
Contractor Agreement with Hospice
Family Care, Inc.[,] to continue to serve
as its Executive Medical Director of
Hospice’’ and that he had ‘‘signed
prescriptions for controlled substances
for ten patients ‘‘after the effective date
of the [July 17, 2012] Board Order.’’ Id.
at 3.
While the Arizona Board’s
investigation was ongoing, Respondent
was also the subject of disciplinary
proceedings brought by the Utah
Division of Occupational and
Professional Licensing against his
licenses to practice osteopathy and
prescribe controlled substances in that
State. GX 11, at 1. On February 4, 2013,
Respondent entered into a Stipulation
and Order with the State in which he
admitted that on May 4, 2012, he had
submitted an application for licensure
as an osteopath and represented on the
application ‘‘that he was not currently
under investigation by any licensing
agency, even though [he] knew he was
currently under investigation in
Arizona.’’ Id. at 3. Respondent admitted
that his conduct constituted both
‘‘unprofessional conduct as defined in
Utah Code Ann. § 58–1–501(2)(a) and
unlawful conduct as defined in Utah
Code Ann. § 58–1–501(e).’’ Id.
Respondent agreed to surrender his
licenses to practice as an osteopath and
to administer and prescribe controlled
substances and to not reapply for such
licenses for a period of five years. Id. On
practice monitor. GX 10, at 4. During the November
9 interview, ‘‘Respondent stated that he did not hire
a practice monitor because he was not actively
practicing in Arizona.’’ Id.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
64943
February 6, 2013, the Division approved
the Order. Id. at 6.
Respondent’s March 2013 DEA
Application, the Tennessee Board
Action, and His Subsequent Address
Changes
On March 4, 2013, Respondent
applied for a new DEA registration at an
address in Chattanooga, Tennessee. GX
6, at 2. On the application, Respondent
was required to answer four liability
questions. With respect to Question
Two, which asked, inter alia, whether
Respondent had ever surrendered (for
cause) his DEA registration, Respondent
answered ‘‘yes.’’ GX 7, at 2. After listing
the incident date as ‘‘7/17/2012’’ and
the incident location as ‘‘Scottsdale,
AZ,’’ Respondent explained the nature
of the incident as follows: ‘‘AN
ADDICTION PATIENT OF MINE
ESCALATED THE USE OF HER
MEDICATIONS AND ENDED UP IN
THE ER. SHE WAS DISCHARGED
FROM THE ER UNHARMED BUT HER
MOTHER COMPLAINED TO THE
ARIZONA OSTEOPATHIC BOARD OF
EXAMINERS. THEY PLACED MY
LICENSE ON SUSPENSION.’’ Id. As for
the ‘‘incident result,’’ Respondent
explained: ‘‘I VOLUNTARILY
SURRENDERED MY ARIZONA
MEDICAL LICENSE AND DEA
REGISTRATION AS I NEW [sic] THAT
I WAS MOVING TO TENNESSEE IN
THE NEAR FUTURE.’’ Id.
As for Question Three, it asked: ‘‘Has
the applicant ever surrendered (for
cause) or had a state professional license
or controlled substance registration
revoked, suspended, denied, restricted,
or placed on probation, or is any such
action pending?’’ Id. Respondent again
answered ‘‘Yes’’ and listed the same
incident date and location as he did in
his previous answer. Id. As for the
nature of the incident, Respondent
explained: ‘‘THE ARIZONA BOARD
. . . PLACED MY LICENSE ON A 5
YEAR PROBATION.’’ Id. He then
explained the incident result as: ‘‘I
VOLUNTARILY SURRENDERED MY
ARIZONA LICENSE AND DEA
REGISTRATION AS I KNEW I WAS
MOVING TO TENNESSE IN THE NEXT
FEW MONTHS.’’ Id. at 3.
Respondent did not disclose on the
application the November 16, 2012
Interim Consent Agreement with the
Arizona Board. See id. He also did not
disclose the February 6, 2013
Stipulation and Order with the State of
Utah. Id.
As found above, the next day,
Respondent was issued a new
registration which authorized him to
dispense controlled substances in
schedules II through V, at a location in
E:\FR\FM\21SEN1.SGM
21SEN1
64944
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
Chattanooga, Tennessee; this
registration did not expire until
February 29, 2016. Shortly thereafter,
Respondent sought to change his
registered address to a location in
Hixson, Tennessee, which the Agency
approved on April 3, 2013. GX 6, at 5.
However, on March 17, 2014,
Respondent entered into a Consent
Order with the Tennessee Board of
Osteopathic Examination. GX 13, at 7.
The Order was based on the July 17,
2012 and November 17, 2012 Arizona
Orders, as well as the Utah Stipulation
and Order. GX 13, at 3–4. Respondent
agreed that the ‘‘disciplinary actions in
Utah and Arizona . . . constitute [sic]
unprofessional conduct’’ in that they
involved ‘‘[u]nprofessional,
dishonorable or unethical conduct’’
which, while it occurred in other States,
was also grounds for discipline in
Tennessee. Id. (citing Tenn. Code Ann.
§§ 63–9–111(b)(1) & (b)(21)).
Respondent further agreed to the
indefinite suspension of his Tennessee
license. Id. at 4. On May 7, 2014, the
Board approved the Order. Id. at 6.
According to Respondent, in July
2014, he moved to Grand Junction,
Colorado, where he was also licensed,
and began working for Dr. Rebecca
Tolby, and worked for her for 11
months. GX 5, at 11 (Resp. Position
Statement). On some date which is not
clear on the record,12 Respondent
sought to modify his registered location
to an address in Colorado; however, the
modification was not approved until
April 6, 2015. GX 6, at 6 (Diversion
Investigator’s (DI) Declaration); see also
GX 7, at 1 (Certification of Registration
History).
In her Declaration, the DI stated that
on December 1, 2014, she phoned
‘‘Respondent regarding his lack of
authority to write prescriptions in the
State of Colorado’’ and offered him ‘‘the
opportunity to surrender [his] DEA
registration.’’ GX 6, at 6. According to
the DI, ‘‘[t]hat same evening . . .
Respondent attempted to modify his
registered address again from Tennessee
to New Mexico.’’ 13 Id. However,
12 In an affidavit attached to his Position
Statement, Respondent asserted that ‘‘[w]hen I
moved to Colorado in 2014, I applied to modify my
DEA registration to my Colorado address.’’ GX 5, at
13. Respondent did not, however, specify the date
on which he applied for the modification. Id.
13 Respondent also obtained an osteopathic
medicine license in New Mexico in May 2012; he
provided the Agency with a contact address in
Albuquerque from December 2014 through
February 2015, but there is no indication in the
record that he practiced in New Mexico.
Respondent admits that the New Mexico Board of
Osteopathic Medical Examiners (NMBOME) had
opened an investigation into his license but that his
license had been renewed on August 19, 2015. GX
5 at 12. However, the NMBOME Web site states that
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
Respondent subsequently changed his
modification request ‘‘back to
Colorado.’’ 14 Id.
The DI’s Investigation of Respondent’s
Controlled Substance Prescribing in
Colorado
On April 30, 2015, the DI served a
Notice of Inspection on five pharmacies
located in Grand Junction, Colorado
seeking to obtain copies of the
prescriptions written by Respondent
and dispensing reports showing the
prescriptions he had written ‘‘from
approximately July 2014 through
February 2015.’’ GX 6, at 7–8. Upon
reviewing the records, the DI prepared
a list by month of 89 controlled
substance prescriptions (some of which
provided for refills) Respondent issued
from July 29, 2014 through December 1,
2014 while practicing in Grand
Junction, Colorado, id. at 7–10; copies of
the prescriptions were submitted for the
record.15 See GXs 14, 15, 20, 21, 22, 23,
24, 25. Moreover, the dispensing reports
obtained from two of the pharmacies
showed that Respondent issued
additional controlled substance
prescriptions even after December 1,
2014, the date on which he was told by
the DI that he was not authorized to
issue such prescriptions in Colorado.
See GX 22, at 7 (report obtained from
Palisade Pharmacy of Palisade, Colorado
showing prescriptions for Tramadol
issued to M.B. on Dec. 18, 2014 (filled
on Dec. 29, 2014) and on January 26,
2015 (filled that day)); GX 25, at 7
(report obtained from Walgreens of
Clifton, Colorado showing prescription
for clonazepam issued to A.O. on Mar.
Respondent’s Pharmacy license expired on March
1, 2016, and that his osteopathic license expired on
July 1, 2016. See https://verification.rld.state.nm.us/
Details.aspx?agency_id=l&license_id=625477.
14 On September 14, 2015 (the same date the
Show Cause Order was served), Respondent’s
registered address was changed to the La Junta
Clinic, 1012 Belmont Avenue, in La Junta,
Colorado. GX 7, at 1.
15 As discussed above, the Government also
alleged that Respondent ‘‘issued multiple
prescriptions to patients within a thirty-day
window, amounting to prescriptions for large
dosages of highly-abused controlled substances.’’
GX 2, at 6. As support for the allegation, the DI
listed 11 patients who received additional
prescriptions within 30 days of having received
prescriptions from Respondent. GX 6, at 10–11.
While Respondent violated federal law when he
issued the prescriptions because he was not
registered in Colorado, the Government did not
allege that any of these prescriptions lacked a
legitimate medical purpose and thus violated 21
CFR 1306.04(a) or a similar provision under
Colorado law. Beyond that, in some instances the
prescriptions were issued 28 days after the previous
prescriptions, which hardly suggests that patients
were seeking refills that were too early. While in
other instances, the time between the prescriptions
was only two or three weeks, the Government did
not address why, given the dosing instruction, the
refill was too early. I thus reject the allegation.
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
2, 2015 and dispensed by pharmacy on
Mar. 3, 2015).
The Colorado Board Proceeding
On April 22, 2016, the Colorado
Medical Board suspended Respondent’s
license to practice medicine pending
proceedings for suspension or
revocation. The suspension was based
on the Board’s finding that there is
‘‘reasonable grounds to believe that
Respondent was guilty of a deliberate
and willful violation of the Medical
Practice Act’’ in that he ‘‘authorized
prescriptions for controlled substances
for at least four patients . . . using
another physician’s DEA registration’’
when he did not have an active DEA
registration number. April 2016
Addendum to Government’s RFAA, GX
27. As of the date of this Decision and
Order, Respondent’s Colorado license
remains suspended. See https://www.
colorado.gov/dora/licensing/Lookup/
Licensedlookup.aspx (visited September
13, 2016).
Respondent’s Position Statement
In support of his Position Statement,
Respondent provided an affidavit.
Therein, Respondent states that he
‘‘take[s] full responsibility for my
actions that resulted in the probation
and ultimate surrender of my Arizona
license’’ and that he since ‘‘learned a
great deal on the proper prescribing of
controlled substances.’’ GX 5, at 11. He
further asserts that ‘‘I did not fully
understand the scope of my initial
restriction, which caused me to
inadvertently violate that restriction.’’
Id.
Respondent further asserts that
‘‘[s]ince 2012, [he] ha[s] taken a number
of steps to ensure that my prescribing
practices are compliant with federal and
state law’’ and that in ‘‘the past year,’’
he has ‘‘been a member of the Colorado
Consortium for Prescription Drug Abuse
Prevention’’ and that ‘‘[t]he program is
helpful to keep abreast of the latest
trends on opioid abuse and strategies for
prevention.’’ Id. at 11–12. He further
states that in 2014, he attended lectures
during a medical convention on the
‘‘Tennessee Substance Abuse Epidemic’’
and ‘‘Office Based Opioid Withdrawal.’’
Id. at 12.
In his affidavit, Respondent states that
‘‘I have had some challenges with my
state medical licenses, all of which arise
from the suspension of my Arizona
license.’’ Id. He then maintains that ‘‘I
have tried to be as transparent as
possible in communicating these issues
to the various state medical boards and
the local DEA offices that have
conducted pre-registration
investigations.’’ Id. at 13.
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
As for his conduct in issuing
controlled substance prescriptions in
Colorado when he was not registered in
the State, Respondent states that he
‘‘was unaware when I moved to
Colorado that I was not able to prescribe
controlled substances until the DEA
actually approved the modification of
my . . . registration to my new
address.’’ Id. Respondent states that he
thought that he could prescribe
controlled substances in Colorado ‘‘so
long as I had submitted my request for
a modification.’’ Id. Respondent then
states that he ‘‘take[s] full
responsibility’’ for this misconduct
which was based on his
‘‘misunderstanding of the law and not
on any intentional effort to circumvent
the’’ CSA. Id. at 14.
According to Respondent, ‘‘[a]s soon
as I understood my mistake, I
immediately stopped prescribing
controlled substances.’’ Id. However, as
found above, the reports of
Respondent’s dispensings that were
provided by the Palisade Pharmacy and
Walgreens show that Respondent issued
additional prescriptions after the DI told
him on December 1, 2014 that he lacked
authority to write prescriptions in
Colorado.16 I thus find that
Respondent’s statement is false.
Respondent further states that he
‘‘understand[s] that the allegations in
the . . . Order to Show Cause are very
serious and that compliance with the
DEA’s regulations on prescribing
controlled substances is crucial to
prevent . . . diversion and abuse of
controlled substances.’’ Id. at 17.
Notably, Respondent did not address
the allegation that he materially falsified
his March 4, 2013 application for a DEA
registration. See generally id. at 10–17.
mstockstill on DSK3G9T082PROD with NOTICES
DISCUSSION
Pursuant to section 303(f) of the
Controlled Substances Act, ‘‘[t]he
Attorney General shall register
practitioners . . . to dispense . . .
controlled substances . . . if the
applicant is authorized to dispense
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Section 303(f) further
provides that an application for a
practitioner’s registration may be denied
upon a determination ‘‘that the issuance
16 While Respondent offered an extensive
explanation of his practice, at least as it existed
prior to the Colorado Board’s suspension of his
medical license, which involved working in rural
Colorado, the Agency has made clear that it does
not consider so-called community impact evidence
relevant in making the public interest
determination in the case of prescribing
practitioners. See Linda Sue Cheek, 76 FR 66972,
66972–73 (2011); Gregory Owen, 74 FR 36751,
36756–57 (2009).
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
of such registration . . . would be
inconsistent with the public interest.’’
Id. In making the public interest
determination, the CSA requires the
consideration of the following factors:
(1) The recommendation of the appropriate
State licensing board or professional
disciplinary authority.
(2) The Applicant’s experience in
dispensing . . . controlled substances.
(3) The Applicant’s conviction record
under Federal or State laws relating to the
manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State,
Federal, or local laws relating to controlled
substances.
(5) Such other conduct which may threaten
the public health and safety.
Id.
‘‘These factors are . . . considered in
the disjunctive.’’ Robert A. Leslie, M.D.,
68 FR 15227, 15230 (2003). I ‘‘may rely
on any one or a combination of factors,
and may give each factor the weight [I]
deem[] appropriate in determining
whether . . . an application for
registration [should be] denied.’’ Id.
Moreover, while I am required to
consider each of the factors, I ‘‘need not
make explicit findings as to each one.’’
MacKay v. DEA, 664 F.3d 808, 816 (10th
Cir. 2011) (quoting Volkman, 567 F.3d
215, 222 (6th Cir. 2009) (quoting Hoxie,
419 F.3d 477, 482 (6th Cir. 2005))).17
Pursuant to section 304(a)(1), the
Attorney General is also authorized to
suspend or revoke a registration ‘‘upon
a finding that the registrant . . . has
materially falsified any application filed
pursuant to or required by this
subchapter.’’ 21 U.S.C. § 824(a)(1). It is
well established that the various
grounds for revocation or suspension of
an existing registration that Congress
enumerated in section 304(a), 21 U.S.C.
§ 824(a), are also properly considered in
deciding whether to grant or deny an
application under section 303. See The
Lawsons, Inc., 72 FR 74334, 74337
(2007); Anthony D. Funches, 64 FR
14267, 14268 (1999); Alan R.
Schankman, 63 FR 45260 (1998); Kuen
H. Chen, 58 FR 65401, 65402 (1993).
Thus, the allegation that Respondent
materially falsified his application is
properly considered in this proceeding.
See Samuel S. Jackson, 72 FR 23848,
23852 (2007). Moreover, just as
materially falsifying an application
provides a basis for revoking an existing
registration without proof of any other
17 ‘‘In short, this is not a contest in which score
is kept; the Agency is not required to mechanically
count up the factors and determine how many favor
the Government and how many favor the registrant.
Rather, it is an inquiry which focuses on protecting
the public interest; what matters is the seriousness
of the registrant’s misconduct.’’ Jayam Krishna-Iyer,
74 FR 459, 462 (2009).
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
64945
misconduct, see 21 U.S.C. 824(a)(1), it
also provides an independent and
adequate ground for denying an
application. The Lawsons, 72 FR at
74338; cf. Bobby Watts, M.D., 58 FR
46995 (1993); Shannon L. Gallentine, 76
FR 45864, 45866 (2011).
In this matter, I conclude that there
are three independent grounds for
denying Respondent’s pending
application. First, he materially falsified
his March 4, 2013 application. Second,
by prescribing controlled substances in
both Arizona and Colorado when he
was not legally authorized to issue such
prescriptions in the respective State, he
violated the CSA and DEA regulations
and thus has committed acts which
render his registration ‘‘inconsistent
with the public interest.’’ 21 U.S.C.
§ 823(f). Third, as a result of the
Colorado Board’s suspension of his
osteopathic license, he lacks authority
under state law to dispense controlled
substances in the State in which he now
seeks registration. See id; see also id.
§ 802(21).
The Material Falsification Allegation
As found above, the evidence shows
that when Respondent submitted his
application for a registration on or about
March 5, 2013, he answered ‘‘Yes’’ to
two liability questions.18 GX 7, at 2.
Question Three asked: ‘‘Has the
applicant ever surrendered for cause or
had a state professional license or
controlled substance registration
revoked, suspended, denied, restricted,
or placed on probation, or is any such
action pending?’’ Respondent checked
the ‘‘yes’’ box and provided the
following information:
Incident Date: 07/17/2012. Incident
Location: Scottsdale, AZ. Incident Nature:
The Arizona Board of Osteopathic Examiners
placed my license on a 5 year probation.
Incident Result: I voluntarily surrendered my
Arizona license and DEA registration as I
knew I was moving to Tennessee in the next
few months.
Id.
The Government alleges that
Respondent’s answer was materially
false because Respondent failed to
disclose the November 2012 Interim
Consent Agreement he entered into with
the Arizona Board and the February
2013 Stipulation and Order he entered
into with the Utah Division of
Occupational and Professional
Licensing. Request for Final Agency
Action, at 11–13. I agree with the
Government that Respondent materially
18 The second question asked Respondent, inter
alia, whether he had ever surrendered his DEA
registration for cause. The Government does not
allege that Respondent materially falsified his
application in answering this question.
E:\FR\FM\21SEN1.SGM
21SEN1
mstockstill on DSK3G9T082PROD with NOTICES
64946
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
falsified his application, but only with
respect to his failure to disclose the
November 2012 Interim Consent
Agreement with Arizona.
The Supreme Court has held that ‘‘the
most common formulation’’ of the
concept of materiality is that ‘‘a
concealment or misrepresentation is
material if it ‘has a natural tendency to
influence, or was capable of influencing,
the decision of’ the decisionmaking
body to which it was addressed.’’
Kungys v. United States, 485 U.S. 759,
770 (1988) (quoting Weinstock v. United
States, 231 F.2d 699, 701 (D.C. Cir.
1956) (other citation omitted)) (quoted
in Samuel S. Jackson, 72 FR 23848,
23852 (2007)); see also United States v.
Wells, 519 U.S. 482, 489 (1997) (quoting
Kungys, 485 U.S. at 770); Arthur H. Bell,
80 FR 50035, 50038 (2015). The Court
has further explained that ‘‘[i]t has
never been the test of materiality that
the misrepresentation or concealment
would more likely than not have
produced an erroneous decision, or
even that it would more likely than not
have triggered an investigation.’’
Kungys, 485 U.S. at 771 (emphasis
added). Rather, the test is ‘‘whether the
misrepresentation or concealment was
predictably capable of affecting, i.e., had
a natural tendency to affect, the official
decision.’’ Id. ‘‘ ‘[T]he ultimate finding
of materiality turns on an interpretation
of substantive law,’ ’’ id. at 772 (int.
quotations and other citation omitted),
and must be shown ‘‘by evidence that is
clear, unequivocal, and convincing.’’ Id.
Respondent’s failure to disclose the
Arizona Interim Consent Agreement
clearly meets the standard of
materiality. As found above, the
Consent Agreement was based on the
Board’s findings that even after the
Board had restricted him from
prescribing controlled substances,
Respondent continued to dispense
controlled substances in that State and
did so for nearly three months after the
effective date of the Board’s Order by
either issuing prescriptions or ordering
the dispensing of controlled substances.
As the evidence shows, Respondent
dispensed 99 prescriptions/orders for
schedule II drugs, 23 prescriptions for
schedule III drugs, and 70 prescriptions
for schedule IV drugs after the effective
date of the Board’s Order and when he
no longer held authority under state law
and DEA regulations. See 21 CFR
1306.03(a) (requiring for a legal
prescription that an individual
practitioner be ‘‘[a]uthorized to
prescribe controlled substances by the
jurisdiction in which he is licensed to
practice his profession and . . . [e]ither
registered or exempted from
registration’’).
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
Moreover, Respondent issued
multiple prescriptions or ordered the
dispensing of controlled substances
even after he surrendered his DEA
registration on July 30, 2012.19 See 21
U.S.C. 843(a)(3) (‘‘It shall be unlawful
for any person knowingly or
intentionally . . . to use in the course
of the . . . dispensing of a controlled
substance, a registration number which
is fictitious, revoked, suspended,
expired, or issued to another person[.]’’);
id. § 822(a)(2) (‘‘Every person who
dispenses . . . any controlled
substance, shall obtain from the
Attorney General a registration . . . .’’);
see also 21 CFR 1306.03(a).
In determining whether the granting
of an application is consistent with the
public interest, the Agency is required
to consider both ‘‘[t]he Applicant’s
experience in dispensing . . .
controlled substances’’ and ‘‘compliance
with applicable State [and] Federal . . .
laws relating to controlled substances.’’
21 U.S.C. 823(f)(2) & (4). Thus, while
Respondent disclosed the July 2012
Arizona Board Order on his application,
his failure to disclose the November
2012 Order was clearly ‘‘capable of
affecting’’ the Agency decision to grant
his application because the Order was
based on the additional misconduct he
committed with respect to the
dispensing of controlled substances
when he no longer held authority under
the CSA and Arizona law. Kungys, 485
U.S. at 771.20
As noted above, in his affidavit,
Respondent did not address his material
falsification of the 2013 application.
However, in his Position Statement, he
admits (through his counsel) that he
‘‘did not provide a complete answer to
the liability question,’’ but then
contends that ‘‘there was never intent
. . . to withhold information from DEA,
to be untruthful, and/or to omit relevant
information to influence DEA’s
decision.’’ GX 5, at 4–5.
However, the statement made by
Respondent’s counsel is not evidence,
see INS v. Phinpathya, 464 U.S. 183,
186 n.6 (1984), and I conclude that
Respondent submitted his 2013 DEA
19 While Respondent’s loss of his state authority
rendered his subsequent issuance of the
prescriptions and orders unlawful under the CSA
even without his having formally surrendered his
DEA registration, Respondent’s continued
dispensing of controlled substances after he
surrendered his registration begs the question of
what consequences he believed were attendant to
the surrender of his DEA registration. However, in
his Position Statement, Respondent does not
address the question.
20 Given this finding, I need not decide whether
Respondent’s failure to disclose the Utah
Stipulation and Order was material to the Agency’s
determination as to whether to grant his application
for registration in Tennessee.
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
application with fraudulent intent. As
explained above, the November 2012
Order, which was issued only three plus
months before he submitted his
application, establishes that Respondent
had engaged in additional misconduct
and disobeyed the Board’s earlier Order
as well as issued prescriptions after he
surrendered his DEA registration. So
too, Respondent’s failure to disclose the
Arizona investigation on his Utah
application is probative evidence of his
intent or lack of mistake in failing to
disclose the November 2012 Arizona
order on his DEA application. See
Arthur H. Bell, 80 FR 50035, 50038
(2015); cf. Fed. R. Evid. R. 404(b)(2).
Accordingly, I conclude that
Respondent materially falsified his
March 4, 2013 application for a DEA
registration in Tennessee. This
conclusion provides reason alone to
deny his pending application.
The Public Interest Factors
In its Request for Final Agency Action
as initially submitted, the Government
argues that Factors Two, Four and Five
support the denial of Respondent’s
application.21 Govt. Request at 14–17. I
21 In the Request for Final Agency Action, the
Government argued that Factor One—The
Recommendation of the Appropriate State
Licensing Board—‘‘neither weighs in favor nor
weighs against the [denial] of Respondent’s’’
application for registration.’’ Req. for Final Agency
Action, at 14.
While Respondent held a Colorado license on the
date the Government submitted its Request for Final
Agency Action, the Board subsequently suspended
his license to practice medicine on the ground that
he authorized controlled substance prescriptions
‘‘using another physician’s DEA registration’’ after
his DEA registration expired. GX 27, at 1. While
Respondent apparently has not had a hearing on
these allegations, the fact remains that he does not
currently possess authority to dispense controlled
substances in Colorado, the State in which he is
seeking registration.
DEA has long held that the possession of state
authority to dispense controlled substances in the
State in which a practitioner engages in
professional practice is a prerequisite for obtaining
a DEA registration in that State. See Frederick
Marsh Blanton, 43 FR 27616, 27617 (1978) (‘‘State
authorization to dispense or otherwise handle
controlled substances is a prerequisite to the
issuance and maintenance of a Federal controlled
substances registration.’’); see also 21 U.S.C.
§ 802(21) (defining ‘‘[t]he term ‘practitioner’ [to]
mean[] a physician . . . or other person licensed,
registered, or otherwise permitted, by the United
States or the jurisdiction in which he practices to
. . . dispense . . . a controlled substance in the
course of professional practice.’’); id. § 823(f) (‘‘The
Attorney General shall register practitioners . . . to
dispense . . . controlled substances . . . if the
applicant is authorized to dispense . . . controlled
substances under the laws of the State in which he
practices.’’); United States v. Moore, 423 U.S. 122,
140–41 (1975) (‘‘In the case of a physician, this
scheme contemplates that he is authorized by the
State to practice medicine and to dispense drugs in
connection with his professional practice.’’). The
Agency has further held that this rule applies even
where a practitioner’s state authority has been
summarily suspended and the State has yet to
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
agree that the evidence with respect to
Factor Two and Four establishes a
prima facie case to deny Respondent’s
application. And having reviewed
Respondent’s Position Statement, I hold
that he has failed to present sufficient
evidence to rebut the conclusion that
his ‘‘registration would be inconsistent
with the public interest.’’ 21 U.S.C.
§ 823(f).
mstockstill on DSK3G9T082PROD with NOTICES
Factors Two and Four—the Applicant’s
Experience in Dispensing Controlled
Substances and Compliance With State
and Federal Laws Related to Controlled
Substances
The Government contends that the
various Arizona Board Orders establish
that Respondent’s experience in
dispensing controlled substances and
his compliance with state and federal
laws related to controlled substances
support the denial of his application
and that the Board’s factual findings and
legal conclusions are entitled to
preclusive effect in this proceeding.
Req. for Final Agency Action, at 14–15.
I agree in part.
Based on its findings that Respondent
deviated from the standard of care in his
treatment of K.K. as well as at least 30
patients, to include prescribing
excessive controlled substances to
chronic pain patients, and that he
ignored pharmacy inquiries and drug
screenings in patients who were clearly
diverting, the Board restricted him from
prescribing or recommending controlled
substances for two years.22 Id. at 4.
provide him/her with a hearing to challenge the
State’s action. See Bourne Pharmacy, 72 FR 18273,
18274 (2007).
Because Respondent’s Colorado medical license
has been suspended, he is no longer currently
authorized to dispense controlled substances in
Colorado, the State in which he seeks registration.
Thus, he no longer meets the CSA’s requirement
that he be authorized to dispense controlled
substances in the State where he is registered. This
conclusion provides a further reason to deny his
application.
22 While the Government argues that the Board’s
findings establish that Respondent ‘‘failed to
comply with state law by deviating from the
standard of care in issuing prescriptions for
controlled substances,’’ the Arizona Board did not
find that he engaged in ‘‘[p]rescribing, dispensing,
or administering controlled substances . . . for
other than therapeutic purposes.’’ See Ariz. Rev.
Stat. § 32–1854. In short, neither of the provisions
the Board found Respondent to have violated make
specific reference to controlled substances but are
provisions generally applicable to all osteopathic
physicians. As such, while Respondent’s conduct
involved controlled substances, the provisions he
violated are not laws related to controlled
substances.
Notwithstanding that the Board did not find that
he prescribed ‘‘for other than therapeutic
purposes,’’ the Board’s findings and conclusions
might well have supported an adverse finding
under Factor Two because ‘‘DEA’s authority to
[deny an application] is not limited to those
instances in which a practitioner intentionally
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
Nonetheless, after the effective date of
the Order, Respondent continued to
issue controlled substance prescriptions
as well order the administration of
controlled substances to hospice
patients. These prescriptions and orders
violated the CSA and DEA regulations
because he lacked the requisite state
authority to dispense controlled
substances. 21 CFR 1306.03(a). See also
Ariz. Rev. Stat. § 32–1854 (25).
Moreover, Respondent issued at least 17
of these prescriptions and orders for
administration even after he
surrendered his registration. 21 U.S.C.
841(a)(1), 843(a)(3), 822(a)(2). Thus, by
itself, Respondent’s unauthorized
dispensing of controlled substances
while practicing in Arizona establishes
that his registration would be
‘‘inconsistent with the public interest.’’
21 U.S.C. 823(f).
Moreover, there is additional
evidence of prescribing violations that
supports this conclusion. As found
above, upon moving to Colorado,
Respondent proceeded to issue
numerous controlled substance
prescriptions without being registered
in that State.
Under DEA’s regulation, where a
registrant seeks to change his registered
location, the registrant must apply to
modify his registration, 21 CFR
§ 1301.51(a), and this regulation clearly
states that a ‘‘request for modification
shall be handled in the same manner as
an application for registration.’’ Id.
§ 1301.51(c). Moreover, under 21 CFR
1301.13(a), ‘‘[n]o person required to be
registered shall engage in any activity
for which registration is required until
the application for registration is
granted and a Certificate of Registration
is issued by the Administrator to such
person.’’ Id.; see also Anthony E. Wicks,
78 FR 62676, 62678 (2013). Thus, a
registrant may ‘‘not engage in any
activity for which registration is
required until the application . . . is
granted and a . . . [r]egistration is
issued.’’ 21 CFR 1301.13(a). See also
Mark Koch 79 FR 18714 (2014).
Here, the evidence shows that
between July 29, 2014 and December 1,
2014, Respondent issued 89
diverts,’’ and ‘‘[a] practitioner who ignores the
warning signs that [his] patients are either
personally abusing or diverting controlled
substances commits ‘acts inconsistent with the
public interest,’ 21 U.S.C. 824(a)(4), even if [he] is
¨
merely gullible or naıve.’’ Jayam Krishna-Iyer, 74
FR 459, 461 n.3 (2009) (citing Paul J. Caragine, Jr.,
63 FR 51592 (1998)). As Caragine explained, even
‘‘[c]areless or negligent handling of controlled
substances creates the opportunity for diversion
and [can] justify revocation or denial’’ of an
application. 63 FR at 51601. The Government did
not, however, raise this theory in the Show Cause
Order.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
64947
prescriptions for controlled substances
while practicing in Grand Junction,
Colorado, when he did not hold a DEA
registration in the State and was
therefore not authorized to dispense
controlled substances in the State. 21
U.S.C. 822(e) (‘‘A separate registration
shall be required at each principal place
of business or professional practice
where the applicant . . . dispenses
controlled substances. . . .’’); 21 CFR
1301.12. Moreover, while Respondent
claims that he was unaware that he
could not issue controlled substance
prescriptions until the Agency approved
his modification request and that he
stopped after he was told by the DI that
he could not write prescriptions until
his request was approved, the evidence
shows that he issued further controlled
substance prescriptions after he was
told by the DI that he lacked authority
to do so in Colorado.
Accordingly, I conclude that
Respondent violated the CSA and DEA
regulations when he prescribed
controlled substances in Colorado
before April 6, 2015. These findings,
particularly when considered in light of
the extent of the Applicant’s prescribing
violations in Arizona, support the
conclusion that granting Applicant’s
application ‘‘would be inconsistent with
the public interest.’’ 21 U.S.C. 823(f).23
SANCTION
Where, as here, the Government has
established grounds to deny an
application, Respondent must then
‘‘present[ ] sufficient mitigating
evidence’’ to show why he can be
entrusted with a new registration.
Samuel S. Jackson, 72 FR 23848, 23853
(2007) (quoting Leo R. Miller, 53 FR
21931, 21932 (1988)). ‘‘ ‘Moreover,
because ‘past performance is the best
predictor of future performance,’ ALRA
Labs, Inc. v. DEA, 54 F.3d 450, 452 (7th
Cir. 1995), [DEA] has repeatedly held
that where [an applicant] has committed
acts inconsistent with the public
interest, the [applicant] must accept
responsibility for [his] actions and
demonstrate that [he] will not engage in
23 As for Factor Three, there is no evidence that
Applicant has been convicted of an offense
‘‘relating to the manufacture, distribution or
dispensing of controlled substances.’’ 21 U.S.C.
823(f)(3). There are, however, a number of reasons
why a person who has engaged in misconduct may
never have been convicted of an offense under this
factor, let alone prosecuted for one. Dewey C.
MacKay, 75 FR 49956, 49973 (2010), pet. for rev.
denied MacKay v. DEA, 664 F.3d 808 (10th Cir.
2011). The Agency has therefore held that ‘‘the
absence of such a conviction is of considerably less
consequence in the public interest inquiry’’ and is
therefore not dispositive. Id.
As for the Government’s arguments with respect
to Factor Five, I consider its contentions in my
discussion of the appropriate sanction.
E:\FR\FM\21SEN1.SGM
21SEN1
mstockstill on DSK3G9T082PROD with NOTICES
64948
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
future misconduct.’’ Jayam Krishna-Iyer,
74 FR 459, 463 (2009) (citing Medicine
Shoppe, 73 FR 364, 387(2008)); see also
Jackson, 72 FR at 23853; John H.
Kennedy, 71 FR 35705, 35709 (2006);
Cuong Tron Tran, 63 FR 64280, 64283
(1998); Prince George Daniels, 60 FR
62884, 62887 (1995).24
So too, an Applicant’s candor during
the course of an investigation and
subsequent proceeding is an important
factor to be considered in determining
whether he has accepted responsibility
for the proven misconduct as well as the
appropriate disposition of the matter.
See Robert F. Hunt, 75 FR 49995, 50004
(2010); Jeri Hassman, 75 FR 8194, 8236
(2010); see also Hoxie v. DEA, 419 F.3d
477, 483 (6th Cir. 2005) (‘‘Candor during
DEA investigations, regardless of the
severity of the violations alleged, is
considered by the DEA to be an
important factor when assessing
whether a physician’s registration is
consistent with the public interest.’’).
While an applicant must accept
responsibility for his misconduct and
demonstrate that he will not engage in
future misconduct in order to establish
that its registration is consistent with
the public interest, DEA has repeatedly
held that these are not the only factors
that are relevant in determining the
appropriate disposition of the matter.
See, e.g., Joseph Gaudio, 74 FR 10083,
10094 (2009); Southwood
Pharmaceuticals, Inc., 72 FR 36487,
36504 (2007). Obviously, the
egregiousness and extent of an
applicant’s misconduct are significant
factors in determining the appropriate
sanction. See Jacobo Dreszer, 76 FR
19386, 19387–88 (2011) (explaining that
a respondent can ‘‘argue that even
though the Government has made out a
prima facie case, his conduct was not so
egregious as to warrant revocation’’);
Paul H. Volkman, 73 FR 30630, 30644
(2008); see also Paul Weir Battershell,
76 FR 44359, 44369 (2011) (imposing
six-month suspension, noting that the
evidence was not limited to security and
recordkeeping violations found at first
inspection and ‘‘manifested a disturbing
pattern of indifference on the part of
[r]espondent to his obligations as a
registrant’’); Gregory D. Owens, 74 FR
36751, 36757 n.22 (2009).
So too, the Agency can consider the
need to deter similar acts, both with
respect to the respondent in a particular
case and the community of registrants.
See Gaudio, 74 FR at 10095 (quoting
Southwood, 71 FR at 36503). Cf.
24 This rule also applies to other grounds that
support the denial of an application, such as where
the Government has proven that an applicant
materially falsified his application. See Jackson, 72
FR, at 23853.
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
McCarthy v. SEC, 406 F.3d 179, 188–89
(2d Cir. 2005) (upholding SEC’s express
adoption of ‘‘deterrence, both specific
and general, as a component in
analyzing the remedial efficacy of
sanctions’’).
Having reviewed Respondent’s
Position Statement, I conclude that he
has failed to produce sufficient evidence
to show why he should be entrusted
with a new registration. With respect to
his acceptance of responsibility,
Respondent states only that he ‘‘accepts
full responsibility for his actions that
lead [sic] to the sanctions imposed by
Arizona’’ and ‘‘regrets and
acknowledges that he prescribed
controlled substances in Colorado while
his modification request was pending.’’
GX 5, at 7–8. Putting aside that the
credibility of Respondent’s statement
cannot be tested through crossexamination because Respondent
waived his right to a hearing, it is
notable that Respondent does not
acknowledge that he materially falsified
his March 2013 application for
registration in Tennessee. Respondent’s
failure to acknowledge his misconduct
in this regard is fatal to his application.
Moreover, even with respect to his
misconduct in prescribing controlled
substances in Colorado, I conclude that
Respondent has not adequately
acknowledged his misconduct. Even
putting aside that ignorance of the law
is no excuse, Respondent’s statement
regarding his actions is less than
forthcoming. As found above,
Respondent asserted that ‘‘[a]s soon as
I understood my mistake, I immediately
stopped prescribing controlled
substances.’’ Yet the evidence shows
that on December 1, 2014, the DI
phoned him and told him that he lacked
authority to issue controlled substance
prescriptions in Colorado. While this
should have been the point at which he
‘‘understood [his] mistake’’ and
‘‘immediately stopped prescribing,’’ the
evidence shows that Respondent issued
additional controlled substance
prescriptions thereafter. In short,
Respondent’s assertion is clearly false
and I therefore also find that he has not
accepted responsibility for his
prescribing in Colorado when he lacked
a DEA registration.
Likewise, while Respondent contends
that he prescribed controlled substances
in violation of the first Arizona order
because he ‘‘did not fully understand
the scope of my initial restriction,
which caused [him] to inadvertently
violate that restriction,’’ having
reviewed that Order, I conclude that it
was more than clear. See GX 8, at 4 (‘‘IT
IS HEREBY FURTHER ORDERED that
[Respondent], holder of osteopathic
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
medical License number 2686 is
restricted from prescribing or
recommending Schedule I, II, III, or IV
controlled substances for a period of
two (2) years from the effective date of
this Order.’’). Indeed, if Respondent did
not fully understand the scope of the
restriction, he had five weeks to contact
the Board and clarify his understanding
before the Order went into effect. Nor is
Respondent’s explanation credible given
that he continued prescribing and
issuing dispensing orders even after he
surrendered his DEA registration. I thus
conclude that Respondent has not
credibly acknowledged his misconduct.
I also conclude that the record as a
whole establishes that Respondent’s
misconduct was egregious given his
material falsification of his March 2013
DEA application, his prescribing of
controlled substances after the Arizona
Board’s Order became effective, and his
continued prescribing in Arizona after
he surrendered his DEA registration. As
for his prescribing in Colorado, even
were I to accept his excuse that he
mistakenly believed that he could
prescribe once he submitted his request
for modification, his issuance of
prescriptions after he was told by the DI
that he lacked authority to write
prescriptions in the State renders this
misconduct egregious as well.
Accordingly, I find that Respondent’s
misconduct warrants denial of his
application for this reason as well. So
too, I find that the Agency’s interest in
deterring similar misconduct by other
applicants who may contemplate
materially falsifying their applications,
as well as by other registrants who may
choose to ignore agency regulations and
prescribe when they lack authority to do
so, supports the denial of his
application.
Of further note, as explained in my
discussion of Factor One, subsequent to
the issuance of the Show Cause Order
and Respondent’s submission of his
Position Statement, the Colorado
Medical Board suspended his medical
license and his license remains
suspended as of the date of this Order.
As a consequence, Respondent no
longer holds authority under state law
to dispense controlled substances in the
State where he is currently registered
and thus no longer meets the statutory
prerequisite for obtaining and
maintaining his registration. See
Frederick Marsh Blanton, 43 FR 27616,
27617 (1978) (‘‘State authorization to
dispense or otherwise handle controlled
substances is a prerequisite to the
issuance and maintenance of a Federal
controlled substances registration.’’); see
also 21 U.S.C. 823(f) (‘‘The Attorney
General shall register practitioners . . .
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 81, No. 183 / Wednesday, September 21, 2016 / Notices
if the applicant is authorized to
dispense . . . controlled substances
under the laws of the State in which he
practices.’’); 21 U.S.C. 802(21) (‘‘[t]he
term ‘practitioner’ means a physician
. . . licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . to distribute,
dispense, [or] administer . . . a
controlled substance in the course of
professional practice’’).25
While the Show Cause Order did not
assert this as a ground for denial of his
application (because it occurred
subsequent to the issuance of the
Order), the Government did serve a
copy of its Addendum which presented
this development to me, on Respondent.
In response to this filing, Respondent
has raised no objection.26 In any event,
there are two other independent and
legally sufficient bases to deny his
application. Accordingly, I will deny his
application.
ORDER
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 28 CFR 0.100(b),
I order that the application of Richard
J. Settles, for a DEA Certificate of
Registration as a practitioner be, and it
hereby is, denied. This Order is effective
immediately.
Dated: September 13, 2016.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2016–22680 Filed 9–20–16; 8:45 am]
accordance with 21 CFR 1301.33(a) on
or before November 21, 2016.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
The
Attorney General has delegated her
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
December 18, 2015, Nanosyn, Inc.,
Nanoscale Combinatorial Synthesis,
3331–B Industrial Drive, Santa Rosa,
California 95403 applied to be registered
as a bulk manufacturer the of following
basic classes of controlled substances:
SUPPLEMENTARY INFORMATION:
BILLING CODE 4410–09–P
Controlled substance
Drug
code
Oxymorphone ...........
Fentanyl ....................
9652 .......
9801 .......
Schedule
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Nanosyn, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
mstockstill on DSK3G9T082PROD with NOTICES
DATES:
25 See also Rezik A. Saqer, 81 FR 22122, 22125–
27 (2016); Sheran Arden Yeates, 71 FR 39130,
39131 (2006); Dominick A. Ricci, 58 FR 51104,
51105 (1993); Bobby Watts, 53 FR 11919, 11920
(1988).
26 DEA has previously held that ‘‘[t]he rules
governing DEA hearings do not require the
formality of amending a show cause order to
comply with the evidence. The Government’s
failure to file an amended Show Cause Order
alleging that Respondent’s state CDS license has
expired does not render the proceeding
fundamentally unfair.’’ Roy E. Berkowitz, 74 FR
36758, 36759–60 (2009); see also Hatem M. Ataya,
81 FR 8221, 8245 (2016) (collecting cases).
VerDate Sep<11>2014
18:19 Sep 20, 2016
Jkt 238001
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufacturers
derivatives of controlled substances in
bulk form.
Dated: September 15, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016–22737 Filed 9–20–16; 8:45 am]
64949
(R.D.).1 Therein, the CALJ found that it
is undisputed that Respondent is
currently without authority to handle
controlled substances in New York, the
State in which he holds DEA
Registration FL2580163. R.D. at 4. The
CALJ thus granted the Government’s
Motion for Summary Disposition and
recommended that I revoke
Respondent’s registration and deny any
pending applications.
Neither party filed exceptions to the
Recommended Decision. Having
reviewed the record, I adopt the CALJ’s
finding that Respondent lacks state
authority to handle controlled
substances in New York, the State in
which he is registered. ‘‘State
authorization to dispense or otherwise
handle controlled substances is a
prerequisite to the issuance and
maintenance of a Federal controlled
substances registration.’’ Frederick
Marsh Blanton, 43 FR 27616, 27617
(1978). See also Rezik A. Saqer, 81 FR
22122, 22124–127 (2016). Thus, once
the Government establishes that an
applicant for a practitioner’s registration
or a practitioner-registrant does not
possess state authority, there are no
further facts to be considered and
revocation is the mandatory sanction
that must be entered under the
Controlled Substances Act. Accordingly,
I will also adopt the CALJ’s
recommendation that I revoke
Respondent’s registration and deny any
pending application to renew or modify
his registration.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a), as well
as 28 CFR 0.100(b), I order that DEA
Certificate of Registration FL2580163
issued to Kevin L. Lowe, M.D., be, and
it hereby is, revoked. I further order that
any pending application of Kevin L.
Lowe, M.D., to renew or modify the
above registration, be, and it hereby is,
denied. This Order is effective
immediately.2
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Kevin L. Lowe, M.D.; Decision and
Order
On May 18, 2016, Chief
Administrative Law Judge John J.
Mulrooney, II (CALJ), issued the
attached Recommended Decision
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
1 All citations to the Recommended Decision are
to the slip opinion issued by the CALJ.
2 Based on Respondent’s acknowledgment that he
has been convicted of conspiring to unlawfully
distribute controlled substances, see Resp.’s Hrng.
Req., at 1–2, I find that the public interest
necessitates that this Order be effective
immediately. 21 CFR 1316.67.
E:\FR\FM\21SEN1.SGM
21SEN1
Agencies
[Federal Register Volume 81, Number 183 (Wednesday, September 21, 2016)]
[Notices]
[Pages 64940-64949]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-22680]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Richard J. Settles, D.O.; Decision and Order
On September 9, 2015, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Richard J. Settles, D.O. (hereinafter, Respondent), of
Grand Junction, Colorado. The Show Cause Order proposed the revocation
of Respondent's DEA Certificate of Registration FS3717975, pursuant to
which he is authorized to dispense controlled substances in schedules
II through V, as a practitioner, at the registered address of 715
Horizon Drive, Suite 200, Grand Junction, Colorado. GX 2, at 1 (citing
21 U.S.C. 824(a)(1) and (4)). The Show Cause Order also proposed the
denial of any pending application to renew or modify Respondent's
registration, on the ground that his ``continued registration is
inconsistent with the public interest.'' Id.
As grounds for the proposed actions, the Government alleged that
Respondent had materially falsified his March 4, 2013 application for
registration. Id. at 2 (21 U.S.C. 824(a)(1)). The Order also alleged
that he had issued prescriptions for controlled substances without
authority to do so under both Arizona and Federal law. Id. at 3 (citing
21 U.S.C. 824(a)(4)).
With respect to the material falsification allegation, the
Government alleged that on March 4, 2013, Respondent applied for a DEA
registration at a location in Chattanooga, Tennessee. Id. at 1. The
Government alleged that Respondent provided a ``yes'' answer to the
application question: ``Has the applicant ever surrendered (for cause)
or had a state professional license or controlled substances
registration revoked, suspended, restricted, or placed on probation, or
is any such action pending?'' and that ``[i]n furtherance of [his]
answer,'' Respondent explained that on July 17, 2012, ``the Arizona
Board of Osteopathic Examiners placed my license on a 5 year
probation,'' and that as a result, ``I voluntarily surrendered my
Arizona license and DEA registration as I knew I was moving to
Tennessee in the next few months.'' Id. at 1-2.
The Government then alleged that Respondent's answer was materially
false because he was ``aware of at least two . . . other state
professional license actions'' when he submitted the application and
failed to disclose them. Id. at 2. The Government alleged that these
actions included a November 17, 2012 Interim Consent Order issued by
the Arizona Board, which restricted Respondent's license to practice
osteopathic medicine pending the Board's investigation into whether he
violated its July 17, 2012 Order by prescribing controlled substances
as his authority to do so had been restricted by that Order. Id. As for
the second Board action, the Government alleged that on February 6,
2013, Respondent entered into a Stipulation and Order with the Utah
Division of Occupational and Professional Licensing, in which he
admitted that he had falsified a May 4, 2012 application for licensure
in that State, because he failed to disclose that he was then under
investigation by the Arizona Board, and that he had surrendered his
Utah license to practice as an osteopath. Id. at 2-3 (citing 21 U.S.C.
824(a)(1), 823(f), 843(a)(4)(A)).
As for the prescribing allegations, the Government alleged that
pursuant to the July 17, 2012 Arizona Board Order, Respondent was
restricted from prescribing schedule I through IV controlled
substances. Id. at 3. The Order alleged that the Board subsequently
found that after the effective date of the Order, Respondent became the
medical director of a hospice program and prescribed controlled
substances to 10 of the program's patients. Id. The Order then alleged
that ``[p]rescribing controlled substances without appropriate
authority is contrary to Federal law.'' Id. at 3 (citations omitted).
Next, the Order alleged that on May 7, 2014, one day before the
Tennessee State Board of Osteopathic Examination issued a Consent Order
which indefinitely suspended his Tennessee license, Respondent applied
to modify his registered address from Tennessee to an address in
Dolores, Colorado. Id. at 4. The Order alleged that Respondent made
several additional requests to modify his registered address,
concluding with his February 18, 2015 request to change his address to
a location in Grand Junction, Colorado and that the Agency approved
this request on March 17, 2015. Id.
The Order then alleged that prior to the Agency's approval of his
modification request, Respondent issued controlled substance
prescriptions in Colorado, ``in violation of 21 U.S.C. 810(10),\1\
822(e), and 841(a)(1).'' Id. at 4 (citing, inter alia, 21 CFR
1301.12(a), 1301.13(a)). Specifically, the Order alleged that ``from
July 2014 through February 2015, [Respondent] issued over 250
prescriptions when [he] lacked the requisite federal authority to issue
prescriptions in Colorado.'' Id. The Order then set forth multiple
instances of such prescriptions. Id. at 5-6. The Order further alleged
that Respondent ``issued multiple prescriptions to patients within a
thirty-day window, amounting to prescriptions for large dosages of
highly abused controlled substances'' and set forth a dozen patients to
whom he issued the prescriptions. Id. at 6-7.
---------------------------------------------------------------------------
\1\ There is no such provision in the CSA.
---------------------------------------------------------------------------
On September 14, 2015, the Show Cause Order, which also notified
Respondent of his right to request a hearing on the allegations or to
submit a written statement in lieu of a hearing, the procedure for
electing either option, and the consequence for failing to elect either
option, was served on Respondent by certified mail, return receipt
requested. GX 4, at 1. Thereafter, on October 14, 2015, Respondent,
through his attorney, filed a document entitled ``Waiver of Hearing,
Statement of Position on the Facts and Law'' (hereinafter ``Position
Statement'') with the Office of Administrative Law Judges. See 21 CFR
1301.43(c); GX 5. Therein, Respondent acknowledged service of the Order
to Show Cause on September 14, 2015, see GX 5 at 5, and explained he
was waiving his right to a hearing and filing his ``Statement of
Position on the Facts and Law regarding the matters alleged in the
Order to Show Cause.'' GX 5, at 2.
On February 29, 2016, the Government forwarded its Request for
Final Agency action, the Investigative Record, and Respondent's
Position Statement. Subsequently, on March 21, 2016, the Government
filed an Addendum to its Request for Final Agency Action (hereinafter,
First
[[Page 64941]]
Addendum). Therein, the Government notified my Office that Respondent
did not file his renewal application until February 2, 2106,\2\ which
was less than 45 days before the expiration date of his registration
(Feb. 29, 2016). Noting that under an agency regulation, ```a
registrant, who has been served with an Order to Show Cause, [must]
file his renewal application at least 45 days before the expiration of
his registration, in order for it to continue in effect past its
expiration date and pending the issuance of a final order,''' and that
Respondent had filed his renewal application less than 45 days prior to
the expiration of his registration, the Government argued that
Respondent's registration had expired and thus, ``the issue to be
considered . . . is whether DEA should grant [his] application . . .
not whether DEA should revoke Respondent's registration.'' Id. at 1
(quoting Paul Weir Battershell, 76 FR 44359, 44361 (2011) (quoting 21
CFR 1301.36(i))).
---------------------------------------------------------------------------
\2\ On the date the Show Cause Order was issued, Respondent was
registered as a practitioner to handle controlled substances in
schedules II-V under DEA Registration FS3717975 at the registered
address of La Junta Clinic, 715 Horizon Drive, Suite 200, Grand
Junction, Colorado; this registration, which was issued on March 5,
2013, was due to expire by its terms on February 29, 2016. GX 1.
---------------------------------------------------------------------------
On April 28, 2016 the Government filed a second Addendum to its
Request for Final Agency Action (hereinafter, Second Addendum).
Therein, the Government advised that ``the Medical Board of Colorado
issued an Order of Suspension which suspended Applicant's Colorado
medical license, effective Friday, April 22, 2016''; the Government
provided a copy of the Board's Order.\3\ Id. at 1; see also Attachment
(GX 27), at 1-2. The Board's Order has been made a part of the
Investigative Record in this proceeding.
---------------------------------------------------------------------------
\3\ The Government certified that a copy of both Addendums was
served on Respondent's counsel. First Addendum, at 3; Second
Addendum at 2.
---------------------------------------------------------------------------
Respondent's Position Statement
Respondent's Position Statement raises various contentions which
warrant discussion prior to my determination of the material facts in
this matter. As a preliminary matter, Respondent asserts that ``in
waiving his right to participate in the hearing[,] [he] did not and
does not waive any rights other than his right to a hearing'' and that
``there is no authority in the regulations of the Agency to waive any
other rights pertaining to the adjudication of this matter.'' GX 5, at
1.
Among other things, Respondent contends that the Administrative Law
Judge is required, ``upon receipt of a waiver of hearing and statement
on the matters of fact and law to determine if the statement is
admissible, and if so make the statement part of the record.'' Id. at 3
(citing 21 CFR 1316.49). Respondent then argues that he ``is entitled
to have the ALJ certify the record in this proceeding to the
Administrator,'' that ``the ALJ's jurisdiction . . . does not terminate
until after he certifies the record,'' that ``a termination of the
proceedings that permits the Government's counsel to determine what
constitutes the record is a clear violation of this regulation,'' and
that ``[t]he ALJ's role and authority is not altered by the waiver of a
hearing.'' Id. at 4 (citing 21 CFR 1316.52).
Respondent is mistaken. Under the Agency's rules, absent the filing
of a request for a hearing on an Order to Show Cause, the Office of
Administrative Law Judges does not acquire jurisdiction over the
matter. Here, Respondent did not file a request for a hearing, and
indeed, explicitly waived his right to a hearing. Accordingly, no
Administrative Law Judge was designated as a presiding officer and
because no hearing was held, there was no record to be certified by a
member of the Office of Administrative Law Judges.
Thus, the Government, while it was required to submit Respondent's
Position Statement with its filing, was otherwise entitled to determine
what evidence it would submit to my Office in support of its Request
for Final Agency action. Moreover, the Government has represented to me
that it provided to Respondent a copy of its Request for Final Agency
Action, the Exhibits, the Addendums, and the Attachment to the Second
Addendum. Accordingly, as the Government has provided Respondent with
all of its filings, Respondent cannot claim that it has been stripped
``of its status as a party to the proceeding.'' \4\ Id. For the same
reason, I reject Respondent's assertion that a ``quagmire . . . would
ensue if the proceedings were cancelled in their entirety \5\ and
Government Counsel were permitted to seek a final order by presenting
DEA's case directly to the Administrator in ex parte communications.''
Id. at 5.
---------------------------------------------------------------------------
\4\ As support for this contention, Respondent quotes 20 CFR
404.929, a regulation applicable to certain hearings conducted by
ALJs on behalf of the Social Security Administration. See GX 5, at
4. This provision has no relevance to this proceeding.
\5\ Respondent offers no explanation as to what further rights
he believes he is entitled to, given that he has waived his right to
a hearing and has filed his Position Statement. Nor does he explain
what he believes remains of the proceeding other than the
Government's submission of its Request for Final Agency Action and
its evidence and my issuance of this Decision and Order.
---------------------------------------------------------------------------
Respondent further argues that under 21 CFR 1301.43(c), I ``may not
terminate the proceeding and issue [my] final order unless `all persons
entitled to a hearing or to participate in a hearing waive . . . their
opportunity for the hearing or to participate in the hearing.'' Id.
(quoting 21 CFR 1301.43(e)) \6\ (emphasis in Respondent's Position
Statement). Respondent then argues that ``DEA is entitled to
participate in the hearing and . . . has counsel of record representing
it,'' but ``has not waived its opportunity to participate in the
hearing.'' Id. at 4. Respondent thus contends that ``canceling the
hearing and allowing the Administrator to issue [his] final order is
not authorized.'' Id.
---------------------------------------------------------------------------
\6\ The correct regulation is 21 CFR 1301.43(e).
---------------------------------------------------------------------------
Once again, Respondent is mistaken. Notwithstanding that an agency
regulation applicable to hearings (21 CFR 1316.42(e)) defines the
``[t]he term person [to] include[] an individual, corporation,
government or governmental subdivision or agency,'' when the Government
initiates an Order to Show Cause proceeding, it is not a ``person
entitled to a hearing'' within the meaning of 21 CFR 1301.43.\7\
Indeed, this language is fairly read as encompassing only the recipient
of the Show Cause Order.
---------------------------------------------------------------------------
\7\ Words take their meaning from the context in which they are
used, and in this regard the language of 21 CFR 1301.43(a) is
probative. It states: ``Any person entitled to a hearing pursuant to
Sec. 1301.32 or Sec. Sec. 1301.34-1301.36 and desiring a hearing
shall, within 30 days after the date of receipt of the order to show
cause . . . file with the Administrator a written request for a
hearing in the form prescribed in Sec. 1316.47 of this chapter.''
The reference provisions apply to applicants for registration whose
applications the Agency is proposing to deny, and the holders of
registrations whose registrations the Agency is proposing to revoke.
As the provision applicable to Respondent states: ``[b]efore
revoking or suspending any registration, the Administrator shall
issue an order to show cause pursuant to Sec. 1301.37 and, if
requested by the registrant, shall hold a hearing pursuant to Sec.
1301.41.'' 21 CFR 1301.36(d) (emphasis added). Here, however,
Respondent did not request a hearing but rather chose to submit a
position statement in lieu thereof.
---------------------------------------------------------------------------
For the same reason, i.e., because it initiated the proceeding,
when the Government initiates an Order to Show Cause proceeding, it is
not a ``person entitled to participate in a hearing pursuant to Sec.
1301.34 or Sec. 1301.35(b).'' 21 CFR 1301.43(b). With respect to Sec.
1301.34, this provision applies to only a narrow category of cases
which are not initiated by the Government--specifically, where an
applicant seeks registration to import schedule I or II controlled
substances. Under this provision, the Agency is required to give notice
to registered manufacturers as
[[Page 64942]]
well as other applicants for registration to manufacturer the same
basic substance, and upon request of such manufacturer or applicant,
the Agency ``shall hold a hearing on the application.'' 21 CFR
1301.34(a). While Government does not initiate the proceeding, it may
intervene in the proceeding as a ``person entitled to participate in a
hearing.'' 21 CFR 1301.43(b). See also e.g., Chattem Chemicals, Inc.,
71 FR 9834, 9834 (2006), pet. for rev. denied sub nom. Penick Corp,
Inc., v. DEA, 491 F.3d 483, 493 (D.C. Cir. 2007); Penick Corp., Inc.,
68 FR 6947, 6947 (2003), pet. for rev. denied sub nom. Noramco, Inc.,
v. DEA, 375 F.3d 1148, 1159 (D.C. Cir. 2004). Indeed, this is the only
circumstance in which the Government can be fairly described as a
``person entitled to participate in a hearing.'' \8\
---------------------------------------------------------------------------
\8\ 21 CFR 1301.43(b) also refers to the provisions of
1301.35(b), which allow for registered bulk manufacturers of a basic
substance in schedule I or II (as well as applicants for
registration to manufacture the basis substance) to ``participate in
a hearing'' when the Government has issued a Show Cause Order
proposing the denial of an application for registration ``to
manufacture in bulk'' the same basic class and the applicant has
requested a hearing. Here too, the Government is not a ``person
entitled to participate in a hearing.'' Rather, it is initiator of
the proceeding.
---------------------------------------------------------------------------
Thus, with respect to this proceeding, the Government is neither a
``person[] entitled to a hearing or to participate in a hearing,'' 21
CFR 1301.43(e), and the only person whose waiver matters for the
purpose of cancelling the hearing is Respondent. Because Respondent has
waived his right to a hearing, I am authorized to issue this ``final
order . . . without a hearing.'' \9\ Id.
---------------------------------------------------------------------------
\9\ The Agency's longstanding and consistent practice is that
where a party waives its right to a hearing, the Government is
entitled to present its evidence directly to the Administrator, who
is the ultimate factfinder. See, e.g., Cf. Reckitt & Colman, Ltd. v.
Administrator, 788 F.2d 22, 26 (quoting 5 U.S.C. 557(b) (``On appeal
from or review of the initial decision, the agency has all the
powers which it would have in making the initial decision . . .
.'')). This practice has been followed in hundreds of cases over the
years.
---------------------------------------------------------------------------
Having reviewed the entire record, including Respondent's Statement
of Position, I make the following factual findings.
FINDINGS OF FACT
Jurisdictional Facts
Respondent, a doctor of osteopathic medicine, previously held DEA
Certificate of Registration FS3717975, pursuant to which he was
authorized to dispense controlled substances in schedules II-V, at the
address of La Junta Clinic, 1012 Belmont Ave., La Junta, Colorado. GX
1. This registration was issued on March 5, 2013, after Respondent
submitted the application which is the subject of the material
falsification allegations. On February 2, 2016, Respondent submitted an
application to renew this registration. First Addendum, at 1. However,
because Respondent had previously been served with the Show Cause
Order, in order for his registration to remain valid pending this
proceeding, he was required to submit his application at least 45 days
before the date on which the registration was due to expire. 21 CFR
1301.36(i). Accordingly, I find that Respondent's registration expired
on February 29, 2016. I further find, however, that Respondent's
application remains pending in this proceeding.\10\
---------------------------------------------------------------------------
\10\ Respondent previously held DEA Certificate of Registration
BS3176105. GX 7, at 3. Pursuant to this registration, Respondent was
authorized to dispense controlled substances in schedules II through
V, at the registered location of 10752 North 89th Place, Suite 218,
Scottsdale, Arizona 85620. GX 9, at 1. However, on July 30, 2012,
Respondent surrendered this registration ``[i]n view of [his]
alleged failure to comply with the Federal requirements pertaining
to controlled substances, and as an indication of my good faith in
desiring to remedy any incorrect or unlawful practice on [his]
part.'' Id. This registration was retired the following day. GX 7,
at 3.
---------------------------------------------------------------------------
The Arizona and Utah Investigations of Respondent
On April 29, 2010, the mother of Respondent's patient K.K. made a
complaint to the Arizona Board of Osteopathic Examiners alleging that
K.K. was a heroin addict and that Respondent was prescribing drugs and
quantities that ``were inappropriate [given] K.K.'s history with
substance abuse.'' GX 8, at 2. The same day, the Board notified
Respondent that it was initiating an investigation. Id. at 1.
Thereafter, Respondent was invited to attend an investigative
hearing which was conducted on September 24, 2011; the hearing was
continued to allow the Board to obtain additional information and
conduct ``a chart review of thirty (30) patients.'' Id. The Board also
ordered Respondent to undergo a psychological evaluation and requested
that he provide additional documentation to it. Id.
On April 10, 2012, the Board notified Respondent ``that the
Investigative Hearing would continue on May 19, 2012.'' Id. On that
date, the Board conducted the hearing with Respondent present and
represented by counsel. Id. Thereafter, the Board issued a decision and
order which made factual findings and legal conclusions regarding
Respondent's prescribing to K.K. as well as its chart review.
With respect to K.K., the Board found that she was Respondent's
patient ``from March 2005 through March 2010, with a lapse in care from
February 2006 to early 2009.'' Id. at 2. The Board found that at K.K.'s
second visit, Respondent prescribed Percocet to her in quantities
ranging from 120 to 180 dosage units each month as well as 90 Xanax and
30 Ambien each month. Id. The Board further found that ``Respondent
failed to obtain prior medical records or to perform a workup on K.K.
and no consultations were ordered.'' Id. It also found that ``[t]he
majority of K.K.'s medications were obtained through Respondent's
office'' and that he ``did not enter into a medication contract with
[her] until May 5, 2010 for Suboxone.'' Id.
Continuing, the Board found that K.K. ``returned to Respondent . .
. in 2009 and . . . was started on'' 90 Percocet and 90 Soma, and that
``[i]n October 2009, K.K. overdosed and was taken to the hospital.''
Id. The Board found that ``Respondent continued'' to provided K.K. with
prescriptions each month for 120 dosage units of Percocet, 90 Xanax,
and 30 Ambien until March 2010, when he increased her Percocet
prescription to 180 du per month. Id. According to the Board, K.K.
overdosed again on March 17, 2010 as well as on April 11, 2010. Id. at
2-3.
With respect to the chart review, the Board found that ``Respondent
prescribed controlled substances to chronic pain patients'' and that
``[p]harmacy inquiries and drug screens were ignored in patients that
were clearly diverting.'' Id. at 3. The Board further found that
``Respondent deviated from the standard of care by failing to'':
(1) ``stop prescribing controlled substances for patients that
had overdosed'';
(2) ``recognize drug seeking behavior in patients'';
(3) ``request prior medical records'';
(4) ``obtain appropriate laboratory testing'';
(5) ``conduct a physical exam in at least one patient'';
(6) ``obtain consultations''; and
(7) ``follow the directions of specialist [sic] or
recommendations when consultations were obtained.''
Id.
The Board thus found that ``Respondent practice[d] medicine in a
manner that harmed or had potential to harm patients and fell below the
community standard . . . and . . . this conduct endangered a patient or
the public's health.'' Id. And the Board concluded that Respondent
engaged in unprofessional conduct by `` `[e]ngaging in the practice of
medicine in a manner that harms or may harm a patient or that the board
determines falls below the community,' '' as well as that he engaged in
`` `[a]ny conduct or practice
[[Page 64943]]
that endangers the public's health or may reasonably be expected to do
so.''' Id. at 4 (quoting Ariz. Rev. Stat. Sec. Sec. 32-1854(6) &
(38)).
Based on the above, the Board censured Respondent and
``restricted'' him ``from prescribing or recommending Schedule I, II,
III or IV controlled substances for a period of two years . . . from''
the Order's effective date. The Board also restricted him from
practicing pain management, imposed a civil penalty of $1,000 and
placed him on probation for a period of five years, the terms of which
included that he ``obey all federal, state and local laws, and rules
governing the practice of medicine in the State of Arizona.'' Id. The
Order became effective on July 17, 2012. GX 10, at 3.
As found above, on July 30, 2012, Respondent voluntarily
surrendered his then DEA registration (BS3176105). Thereafter, on
October 12, 2012, the Board received information form anonymous sources
that Respondent ``may be prescribing controlled substances.'' GX 16, at
1. In response, the Board queried the Board of Pharmacy's Controlled
Substances Prescription Monitoring Program ``for all controlled
substances written or ordered by [Respondent] from June 11, 2012
through October 15, 2012.'' Id. The query showed that between July 17,
2012 and October 15, 2012, Respondent had issued 99 prescriptions for
schedule II drugs, 23 prescriptions for schedule III drugs, and 70
prescriptions for schedule IV drugs. Id. at 1-2. The Board identified
one patient Respondent saw at his office who received a prescription
for temazepam on August 21, 2012, and 11 patients at hospices in Tuscon
and Mesa to whom he either prescribed or ordered the dispensing of
controlled substances, which included morphine, hydromorphone,
oxycodone, lorazepam and temazepam. Id. at 2-6. Moreover, Respondent
issued 17 controlled substance prescriptions or orders for the
dispensing of controlled substances for 12 patients after he
surrendered his DEA registration. Id.
On November 9, 2012, Respondent was interviewed by the Board and
admitted ``that he had signed prescriptions for Schedule I, II, III or
IV controlled substances after the Effective Date'' of the Order. GX
10, at 4. Respondent denied having ``written prescriptions for patients
in his private practice'' and ``stated that he had only written or
authorized prescriptions in his capacity as the . . . medical director
for various hospice locations.'' \11\ Id.
---------------------------------------------------------------------------
\11\ Under the probationary terms of the July 17, 2012 Order,
Respondent was required to hire a practice monitor. GX 10, at 4.
During the November 9 interview, ``Respondent stated that he did not
hire a practice monitor because he was not actively practicing in
Arizona.'' Id.
---------------------------------------------------------------------------
On November 16, 2012, Respondent entered into an Interim Consent
Agreement which the Board approved the following day. Id. at 2, 5.
Respondent admitted to the findings of fact contained therein,
including that he had prescribed or ordered controlled substances after
the July 17, 2012 Order became effective, as well as the legal
conclusion that he had engaged in unprofessional conduct by
``[v]iolating a formal order, probation or a stipulation issued by the
board.'' Id. at 1, 4. The Board then ordered that Respondent be
``restricted from practicing medicine until the investigation'' was
completed and ``he appear[ed] before the Board . . . for resolution''
of the matter. Id. at 4.
On May 12, 2014, Respondent entered into a Consent Agreement and
Order for Voluntary Surrender of Licensee. GX 12, at 1, 5. Therein,
Respondent waived his right to a hearing before the Board. Id. at 2.
The Board found, inter alia, that on August 1, 2012, Respondent had
``entered into an Independent Contractor Agreement with Hospice Family
Care, Inc.[,] to continue to serve as its Executive Medical Director of
Hospice'' and that he had ``signed prescriptions for controlled
substances for ten patients ``after the effective date of the [July 17,
2012] Board Order.'' Id. at 3.
While the Arizona Board's investigation was ongoing, Respondent was
also the subject of disciplinary proceedings brought by the Utah
Division of Occupational and Professional Licensing against his
licenses to practice osteopathy and prescribe controlled substances in
that State. GX 11, at 1. On February 4, 2013, Respondent entered into a
Stipulation and Order with the State in which he admitted that on May
4, 2012, he had submitted an application for licensure as an osteopath
and represented on the application ``that he was not currently under
investigation by any licensing agency, even though [he] knew he was
currently under investigation in Arizona.'' Id. at 3. Respondent
admitted that his conduct constituted both ``unprofessional conduct as
defined in Utah Code Ann. Sec. 58-1-501(2)(a) and unlawful conduct as
defined in Utah Code Ann. Sec. 58-1-501(e).'' Id. Respondent agreed to
surrender his licenses to practice as an osteopath and to administer
and prescribe controlled substances and to not reapply for such
licenses for a period of five years. Id. On February 6, 2013, the
Division approved the Order. Id. at 6.
Respondent's March 2013 DEA Application, the Tennessee Board Action,
and His Subsequent Address Changes
On March 4, 2013, Respondent applied for a new DEA registration at
an address in Chattanooga, Tennessee. GX 6, at 2. On the application,
Respondent was required to answer four liability questions. With
respect to Question Two, which asked, inter alia, whether Respondent
had ever surrendered (for cause) his DEA registration, Respondent
answered ``yes.'' GX 7, at 2. After listing the incident date as ``7/
17/2012'' and the incident location as ``Scottsdale, AZ,'' Respondent
explained the nature of the incident as follows: ``AN ADDICTION PATIENT
OF MINE ESCALATED THE USE OF HER MEDICATIONS AND ENDED UP IN THE ER.
SHE WAS DISCHARGED FROM THE ER UNHARMED BUT HER MOTHER COMPLAINED TO
THE ARIZONA OSTEOPATHIC BOARD OF EXAMINERS. THEY PLACED MY LICENSE ON
SUSPENSION.'' Id. As for the ``incident result,'' Respondent explained:
``I VOLUNTARILY SURRENDERED MY ARIZONA MEDICAL LICENSE AND DEA
REGISTRATION AS I NEW [sic] THAT I WAS MOVING TO TENNESSEE IN THE NEAR
FUTURE.'' Id.
As for Question Three, it asked: ``Has the applicant ever
surrendered (for cause) or had a state professional license or
controlled substance registration revoked, suspended, denied,
restricted, or placed on probation, or is any such action pending?''
Id. Respondent again answered ``Yes'' and listed the same incident date
and location as he did in his previous answer. Id. As for the nature of
the incident, Respondent explained: ``THE ARIZONA BOARD . . . PLACED MY
LICENSE ON A 5 YEAR PROBATION.'' Id. He then explained the incident
result as: ``I VOLUNTARILY SURRENDERED MY ARIZONA LICENSE AND DEA
REGISTRATION AS I KNEW I WAS MOVING TO TENNESSE IN THE NEXT FEW
MONTHS.'' Id. at 3.
Respondent did not disclose on the application the November 16,
2012 Interim Consent Agreement with the Arizona Board. See id. He also
did not disclose the February 6, 2013 Stipulation and Order with the
State of Utah. Id.
As found above, the next day, Respondent was issued a new
registration which authorized him to dispense controlled substances in
schedules II through V, at a location in
[[Page 64944]]
Chattanooga, Tennessee; this registration did not expire until February
29, 2016. Shortly thereafter, Respondent sought to change his
registered address to a location in Hixson, Tennessee, which the Agency
approved on April 3, 2013. GX 6, at 5.
However, on March 17, 2014, Respondent entered into a Consent Order
with the Tennessee Board of Osteopathic Examination. GX 13, at 7. The
Order was based on the July 17, 2012 and November 17, 2012 Arizona
Orders, as well as the Utah Stipulation and Order. GX 13, at 3-4.
Respondent agreed that the ``disciplinary actions in Utah and Arizona .
. . constitute [sic] unprofessional conduct'' in that they involved
``[u]nprofessional, dishonorable or unethical conduct'' which, while it
occurred in other States, was also grounds for discipline in Tennessee.
Id. (citing Tenn. Code Ann. Sec. Sec. 63-9-111(b)(1) & (b)(21)).
Respondent further agreed to the indefinite suspension of his Tennessee
license. Id. at 4. On May 7, 2014, the Board approved the Order. Id. at
6.
According to Respondent, in July 2014, he moved to Grand Junction,
Colorado, where he was also licensed, and began working for Dr. Rebecca
Tolby, and worked for her for 11 months. GX 5, at 11 (Resp. Position
Statement). On some date which is not clear on the record,\12\
Respondent sought to modify his registered location to an address in
Colorado; however, the modification was not approved until April 6,
2015. GX 6, at 6 (Diversion Investigator's (DI) Declaration); see also
GX 7, at 1 (Certification of Registration History).
---------------------------------------------------------------------------
\12\ In an affidavit attached to his Position Statement,
Respondent asserted that ``[w]hen I moved to Colorado in 2014, I
applied to modify my DEA registration to my Colorado address.'' GX
5, at 13. Respondent did not, however, specify the date on which he
applied for the modification. Id.
---------------------------------------------------------------------------
In her Declaration, the DI stated that on December 1, 2014, she
phoned ``Respondent regarding his lack of authority to write
prescriptions in the State of Colorado'' and offered him ``the
opportunity to surrender [his] DEA registration.'' GX 6, at 6.
According to the DI, ``[t]hat same evening . . . Respondent attempted
to modify his registered address again from Tennessee to New Mexico.''
\13\ Id. However, Respondent subsequently changed his modification
request ``back to Colorado.'' \14\ Id.
---------------------------------------------------------------------------
\13\ Respondent also obtained an osteopathic medicine license in
New Mexico in May 2012; he provided the Agency with a contact
address in Albuquerque from December 2014 through February 2015, but
there is no indication in the record that he practiced in New
Mexico. Respondent admits that the New Mexico Board of Osteopathic
Medical Examiners (NMBOME) had opened an investigation into his
license but that his license had been renewed on August 19, 2015. GX
5 at 12. However, the NMBOME Web site states that Respondent's
Pharmacy license expired on March 1, 2016, and that his osteopathic
license expired on July 1, 2016. See https://verification.rld.state.nm.us/Details.aspx?agency_id=l&license_id=625477.
\14\ On September 14, 2015 (the same date the Show Cause Order
was served), Respondent's registered address was changed to the La
Junta Clinic, 1012 Belmont Avenue, in La Junta, Colorado. GX 7, at
1.
---------------------------------------------------------------------------
The DI's Investigation of Respondent's Controlled Substance Prescribing
in Colorado
On April 30, 2015, the DI served a Notice of Inspection on five
pharmacies located in Grand Junction, Colorado seeking to obtain copies
of the prescriptions written by Respondent and dispensing reports
showing the prescriptions he had written ``from approximately July 2014
through February 2015.'' GX 6, at 7-8. Upon reviewing the records, the
DI prepared a list by month of 89 controlled substance prescriptions
(some of which provided for refills) Respondent issued from July 29,
2014 through December 1, 2014 while practicing in Grand Junction,
Colorado, id. at 7-10; copies of the prescriptions were submitted for
the record.\15\ See GXs 14, 15, 20, 21, 22, 23, 24, 25. Moreover, the
dispensing reports obtained from two of the pharmacies showed that
Respondent issued additional controlled substance prescriptions even
after December 1, 2014, the date on which he was told by the DI that he
was not authorized to issue such prescriptions in Colorado. See GX 22,
at 7 (report obtained from Palisade Pharmacy of Palisade, Colorado
showing prescriptions for Tramadol issued to M.B. on Dec. 18, 2014
(filled on Dec. 29, 2014) and on January 26, 2015 (filled that day));
GX 25, at 7 (report obtained from Walgreens of Clifton, Colorado
showing prescription for clonazepam issued to A.O. on Mar. 2, 2015 and
dispensed by pharmacy on Mar. 3, 2015).
---------------------------------------------------------------------------
\15\ As discussed above, the Government also alleged that
Respondent ``issued multiple prescriptions to patients within a
thirty-day window, amounting to prescriptions for large dosages of
highly-abused controlled substances.'' GX 2, at 6. As support for
the allegation, the DI listed 11 patients who received additional
prescriptions within 30 days of having received prescriptions from
Respondent. GX 6, at 10-11. While Respondent violated federal law
when he issued the prescriptions because he was not registered in
Colorado, the Government did not allege that any of these
prescriptions lacked a legitimate medical purpose and thus violated
21 CFR 1306.04(a) or a similar provision under Colorado law. Beyond
that, in some instances the prescriptions were issued 28 days after
the previous prescriptions, which hardly suggests that patients were
seeking refills that were too early. While in other instances, the
time between the prescriptions was only two or three weeks, the
Government did not address why, given the dosing instruction, the
refill was too early. I thus reject the allegation.
---------------------------------------------------------------------------
The Colorado Board Proceeding
On April 22, 2016, the Colorado Medical Board suspended
Respondent's license to practice medicine pending proceedings for
suspension or revocation. The suspension was based on the Board's
finding that there is ``reasonable grounds to believe that Respondent
was guilty of a deliberate and willful violation of the Medical
Practice Act'' in that he ``authorized prescriptions for controlled
substances for at least four patients . . . using another physician's
DEA registration'' when he did not have an active DEA registration
number. April 2016 Addendum to Government's RFAA, GX 27. As of the date
of this Decision and Order, Respondent's Colorado license remains
suspended. See https://www.colorado.gov/dora/licensing/Lookup/Licensedlookup.aspx (visited September 13, 2016).
Respondent's Position Statement
In support of his Position Statement, Respondent provided an
affidavit. Therein, Respondent states that he ``take[s] full
responsibility for my actions that resulted in the probation and
ultimate surrender of my Arizona license'' and that he since ``learned
a great deal on the proper prescribing of controlled substances.'' GX
5, at 11. He further asserts that ``I did not fully understand the
scope of my initial restriction, which caused me to inadvertently
violate that restriction.'' Id.
Respondent further asserts that ``[s]ince 2012, [he] ha[s] taken a
number of steps to ensure that my prescribing practices are compliant
with federal and state law'' and that in ``the past year,'' he has
``been a member of the Colorado Consortium for Prescription Drug Abuse
Prevention'' and that ``[t]he program is helpful to keep abreast of the
latest trends on opioid abuse and strategies for prevention.'' Id. at
11-12. He further states that in 2014, he attended lectures during a
medical convention on the ``Tennessee Substance Abuse Epidemic'' and
``Office Based Opioid Withdrawal.'' Id. at 12.
In his affidavit, Respondent states that ``I have had some
challenges with my state medical licenses, all of which arise from the
suspension of my Arizona license.'' Id. He then maintains that ``I have
tried to be as transparent as possible in communicating these issues to
the various state medical boards and the local DEA offices that have
conducted pre-registration investigations.'' Id. at 13.
[[Page 64945]]
As for his conduct in issuing controlled substance prescriptions in
Colorado when he was not registered in the State, Respondent states
that he ``was unaware when I moved to Colorado that I was not able to
prescribe controlled substances until the DEA actually approved the
modification of my . . . registration to my new address.'' Id.
Respondent states that he thought that he could prescribe controlled
substances in Colorado ``so long as I had submitted my request for a
modification.'' Id. Respondent then states that he ``take[s] full
responsibility'' for this misconduct which was based on his
``misunderstanding of the law and not on any intentional effort to
circumvent the'' CSA. Id. at 14.
According to Respondent, ``[a]s soon as I understood my mistake, I
immediately stopped prescribing controlled substances.'' Id. However,
as found above, the reports of Respondent's dispensings that were
provided by the Palisade Pharmacy and Walgreens show that Respondent
issued additional prescriptions after the DI told him on December 1,
2014 that he lacked authority to write prescriptions in Colorado.\16\ I
thus find that Respondent's statement is false.
---------------------------------------------------------------------------
\16\ While Respondent offered an extensive explanation of his
practice, at least as it existed prior to the Colorado Board's
suspension of his medical license, which involved working in rural
Colorado, the Agency has made clear that it does not consider so-
called community impact evidence relevant in making the public
interest determination in the case of prescribing practitioners. See
Linda Sue Cheek, 76 FR 66972, 66972-73 (2011); Gregory Owen, 74 FR
36751, 36756-57 (2009).
---------------------------------------------------------------------------
Respondent further states that he ``understand[s] that the
allegations in the . . . Order to Show Cause are very serious and that
compliance with the DEA's regulations on prescribing controlled
substances is crucial to prevent . . . diversion and abuse of
controlled substances.'' Id. at 17. Notably, Respondent did not address
the allegation that he materially falsified his March 4, 2013
application for a DEA registration. See generally id. at 10-17.
DISCUSSION
Pursuant to section 303(f) of the Controlled Substances Act,
``[t]he Attorney General shall register practitioners . . . to dispense
. . . controlled substances . . . if the applicant is authorized to
dispense controlled substances under the laws of the State in which he
practices.'' 21 U.S.C. 823(f). Section 303(f) further provides that an
application for a practitioner's registration may be denied upon a
determination ``that the issuance of such registration . . . would be
inconsistent with the public interest.'' Id. In making the public
interest determination, the CSA requires the consideration of the
following factors:
(1) The recommendation of the appropriate State licensing board
or professional disciplinary authority.
(2) The Applicant's experience in dispensing . . . controlled
substances.
(3) The Applicant's conviction record under Federal or State
laws relating to the manufacture, distribution, or dispensing of
controlled substances.
(4) Compliance with applicable State, Federal, or local laws
relating to controlled substances.
(5) Such other conduct which may threaten the public health and
safety.
Id.
``These factors are . . . considered in the disjunctive.'' Robert
A. Leslie, M.D., 68 FR 15227, 15230 (2003). I ``may rely on any one or
a combination of factors, and may give each factor the weight [I]
deem[] appropriate in determining whether . . . an application for
registration [should be] denied.'' Id. Moreover, while I am required to
consider each of the factors, I ``need not make explicit findings as to
each one.'' MacKay v. DEA, 664 F.3d 808, 816 (10th Cir. 2011) (quoting
Volkman, 567 F.3d 215, 222 (6th Cir. 2009) (quoting Hoxie, 419 F.3d
477, 482 (6th Cir. 2005))).\17\
---------------------------------------------------------------------------
\17\ ``In short, this is not a contest in which score is kept;
the Agency is not required to mechanically count up the factors and
determine how many favor the Government and how many favor the
registrant. Rather, it is an inquiry which focuses on protecting the
public interest; what matters is the seriousness of the registrant's
misconduct.'' Jayam Krishna-Iyer, 74 FR 459, 462 (2009).
---------------------------------------------------------------------------
Pursuant to section 304(a)(1), the Attorney General is also
authorized to suspend or revoke a registration ``upon a finding that
the registrant . . . has materially falsified any application filed
pursuant to or required by this subchapter.'' 21 U.S.C. Sec.
824(a)(1). It is well established that the various grounds for
revocation or suspension of an existing registration that Congress
enumerated in section 304(a), 21 U.S.C. Sec. 824(a), are also properly
considered in deciding whether to grant or deny an application under
section 303. See The Lawsons, Inc., 72 FR 74334, 74337 (2007); Anthony
D. Funches, 64 FR 14267, 14268 (1999); Alan R. Schankman, 63 FR 45260
(1998); Kuen H. Chen, 58 FR 65401, 65402 (1993).
Thus, the allegation that Respondent materially falsified his
application is properly considered in this proceeding. See Samuel S.
Jackson, 72 FR 23848, 23852 (2007). Moreover, just as materially
falsifying an application provides a basis for revoking an existing
registration without proof of any other misconduct, see 21 U.S.C.
824(a)(1), it also provides an independent and adequate ground for
denying an application. The Lawsons, 72 FR at 74338; cf. Bobby Watts,
M.D., 58 FR 46995 (1993); Shannon L. Gallentine, 76 FR 45864, 45866
(2011).
In this matter, I conclude that there are three independent grounds
for denying Respondent's pending application. First, he materially
falsified his March 4, 2013 application. Second, by prescribing
controlled substances in both Arizona and Colorado when he was not
legally authorized to issue such prescriptions in the respective State,
he violated the CSA and DEA regulations and thus has committed acts
which render his registration ``inconsistent with the public
interest.'' 21 U.S.C. Sec. 823(f). Third, as a result of the Colorado
Board's suspension of his osteopathic license, he lacks authority under
state law to dispense controlled substances in the State in which he
now seeks registration. See id; see also id. Sec. 802(21).
The Material Falsification Allegation
As found above, the evidence shows that when Respondent submitted
his application for a registration on or about March 5, 2013, he
answered ``Yes'' to two liability questions.\18\ GX 7, at 2. Question
Three asked: ``Has the applicant ever surrendered for cause or had a
state professional license or controlled substance registration
revoked, suspended, denied, restricted, or placed on probation, or is
any such action pending?'' Respondent checked the ``yes'' box and
provided the following information:
---------------------------------------------------------------------------
\18\ The second question asked Respondent, inter alia, whether
he had ever surrendered his DEA registration for cause. The
Government does not allege that Respondent materially falsified his
application in answering this question.
Incident Date: 07/17/2012. Incident Location: Scottsdale, AZ.
Incident Nature: The Arizona Board of Osteopathic Examiners placed
my license on a 5 year probation. Incident Result: I voluntarily
surrendered my Arizona license and DEA registration as I knew I was
---------------------------------------------------------------------------
moving to Tennessee in the next few months.
Id.
The Government alleges that Respondent's answer was materially
false because Respondent failed to disclose the November 2012 Interim
Consent Agreement he entered into with the Arizona Board and the
February 2013 Stipulation and Order he entered into with the Utah
Division of Occupational and Professional Licensing. Request for Final
Agency Action, at 11-13. I agree with the Government that Respondent
materially
[[Page 64946]]
falsified his application, but only with respect to his failure to
disclose the November 2012 Interim Consent Agreement with Arizona.
The Supreme Court has held that ``the most common formulation'' of
the concept of materiality is that ``a concealment or misrepresentation
is material if it `has a natural tendency to influence, or was capable
of influencing, the decision of' the decisionmaking body to which it
was addressed.'' Kungys v. United States, 485 U.S. 759, 770 (1988)
(quoting Weinstock v. United States, 231 F.2d 699, 701 (D.C. Cir. 1956)
(other citation omitted)) (quoted in Samuel S. Jackson, 72 FR 23848,
23852 (2007)); see also United States v. Wells, 519 U.S. 482, 489
(1997) (quoting Kungys, 485 U.S. at 770); Arthur H. Bell, 80 FR 50035,
50038 (2015). The Court has further explained that ``[i]t has never
been the test of materiality that the misrepresentation or concealment
would more likely than not have produced an erroneous decision, or even
that it would more likely than not have triggered an investigation.''
Kungys, 485 U.S. at 771 (emphasis added). Rather, the test is ``whether
the misrepresentation or concealment was predictably capable of
affecting, i.e., had a natural tendency to affect, the official
decision.'' Id. `` `[T]he ultimate finding of materiality turns on an
interpretation of substantive law,' '' id. at 772 (int. quotations and
other citation omitted), and must be shown ``by evidence that is clear,
unequivocal, and convincing.'' Id.
Respondent's failure to disclose the Arizona Interim Consent
Agreement clearly meets the standard of materiality. As found above,
the Consent Agreement was based on the Board's findings that even after
the Board had restricted him from prescribing controlled substances,
Respondent continued to dispense controlled substances in that State
and did so for nearly three months after the effective date of the
Board's Order by either issuing prescriptions or ordering the
dispensing of controlled substances. As the evidence shows, Respondent
dispensed 99 prescriptions/orders for schedule II drugs, 23
prescriptions for schedule III drugs, and 70 prescriptions for schedule
IV drugs after the effective date of the Board's Order and when he no
longer held authority under state law and DEA regulations. See 21 CFR
1306.03(a) (requiring for a legal prescription that an individual
practitioner be ``[a]uthorized to prescribe controlled substances by
the jurisdiction in which he is licensed to practice his profession and
. . . [e]ither registered or exempted from registration'').
Moreover, Respondent issued multiple prescriptions or ordered the
dispensing of controlled substances even after he surrendered his DEA
registration on July 30, 2012.\19\ See 21 U.S.C. 843(a)(3) (``It shall
be unlawful for any person knowingly or intentionally . . . to use in
the course of the . . . dispensing of a controlled substance, a
registration number which is fictitious, revoked, suspended, expired,
or issued to another person[.]''); id. Sec. 822(a)(2) (``Every person
who dispenses . . . any controlled substance, shall obtain from the
Attorney General a registration . . . .''); see also 21 CFR 1306.03(a).
---------------------------------------------------------------------------
\19\ While Respondent's loss of his state authority rendered his
subsequent issuance of the prescriptions and orders unlawful under
the CSA even without his having formally surrendered his DEA
registration, Respondent's continued dispensing of controlled
substances after he surrendered his registration begs the question
of what consequences he believed were attendant to the surrender of
his DEA registration. However, in his Position Statement, Respondent
does not address the question.
---------------------------------------------------------------------------
In determining whether the granting of an application is consistent
with the public interest, the Agency is required to consider both
``[t]he Applicant's experience in dispensing . . . controlled
substances'' and ``compliance with applicable State [and] Federal . . .
laws relating to controlled substances.'' 21 U.S.C. 823(f)(2) & (4).
Thus, while Respondent disclosed the July 2012 Arizona Board Order on
his application, his failure to disclose the November 2012 Order was
clearly ``capable of affecting'' the Agency decision to grant his
application because the Order was based on the additional misconduct he
committed with respect to the dispensing of controlled substances when
he no longer held authority under the CSA and Arizona law. Kungys, 485
U.S. at 771.\20\
---------------------------------------------------------------------------
\20\ Given this finding, I need not decide whether Respondent's
failure to disclose the Utah Stipulation and Order was material to
the Agency's determination as to whether to grant his application
for registration in Tennessee.
---------------------------------------------------------------------------
As noted above, in his affidavit, Respondent did not address his
material falsification of the 2013 application. However, in his
Position Statement, he admits (through his counsel) that he ``did not
provide a complete answer to the liability question,'' but then
contends that ``there was never intent . . . to withhold information
from DEA, to be untruthful, and/or to omit relevant information to
influence DEA's decision.'' GX 5, at 4-5.
However, the statement made by Respondent's counsel is not
evidence, see INS v. Phinpathya, 464 U.S. 183, 186 n.6 (1984), and I
conclude that Respondent submitted his 2013 DEA application with
fraudulent intent. As explained above, the November 2012 Order, which
was issued only three plus months before he submitted his application,
establishes that Respondent had engaged in additional misconduct and
disobeyed the Board's earlier Order as well as issued prescriptions
after he surrendered his DEA registration. So too, Respondent's failure
to disclose the Arizona investigation on his Utah application is
probative evidence of his intent or lack of mistake in failing to
disclose the November 2012 Arizona order on his DEA application. See
Arthur H. Bell, 80 FR 50035, 50038 (2015); cf. Fed. R. Evid. R.
404(b)(2). Accordingly, I conclude that Respondent materially falsified
his March 4, 2013 application for a DEA registration in Tennessee. This
conclusion provides reason alone to deny his pending application.
The Public Interest Factors
In its Request for Final Agency Action as initially submitted, the
Government argues that Factors Two, Four and Five support the denial of
Respondent's application.\21\ Govt. Request at 14-17. I
[[Page 64947]]
agree that the evidence with respect to Factor Two and Four establishes
a prima facie case to deny Respondent's application. And having
reviewed Respondent's Position Statement, I hold that he has failed to
present sufficient evidence to rebut the conclusion that his
``registration would be inconsistent with the public interest.'' 21
U.S.C. Sec. 823(f).
---------------------------------------------------------------------------
\21\ In the Request for Final Agency Action, the Government
argued that Factor One--The Recommendation of the Appropriate State
Licensing Board--``neither weighs in favor nor weighs against the
[denial] of Respondent's'' application for registration.'' Req. for
Final Agency Action, at 14.
While Respondent held a Colorado license on the date the
Government submitted its Request for Final Agency Action, the Board
subsequently suspended his license to practice medicine on the
ground that he authorized controlled substance prescriptions ``using
another physician's DEA registration'' after his DEA registration
expired. GX 27, at 1. While Respondent apparently has not had a
hearing on these allegations, the fact remains that he does not
currently possess authority to dispense controlled substances in
Colorado, the State in which he is seeking registration.
DEA has long held that the possession of state authority to
dispense controlled substances in the State in which a practitioner
engages in professional practice is a prerequisite for obtaining a
DEA registration in that State. See Frederick Marsh Blanton, 43 FR
27616, 27617 (1978) (``State authorization to dispense or otherwise
handle controlled substances is a prerequisite to the issuance and
maintenance of a Federal controlled substances registration.''); see
also 21 U.S.C. Sec. 802(21) (defining ``[t]he term `practitioner'
[to] mean[] a physician . . . or other person licensed, registered,
or otherwise permitted, by the United States or the jurisdiction in
which he practices to . . . dispense . . . a controlled substance in
the course of professional practice.''); id. Sec. 823(f) (``The
Attorney General shall register practitioners . . . to dispense . .
. controlled substances . . . if the applicant is authorized to
dispense . . . controlled substances under the laws of the State in
which he practices.''); United States v. Moore, 423 U.S. 122, 140-41
(1975) (``In the case of a physician, this scheme contemplates that
he is authorized by the State to practice medicine and to dispense
drugs in connection with his professional practice.''). The Agency
has further held that this rule applies even where a practitioner's
state authority has been summarily suspended and the State has yet
to provide him/her with a hearing to challenge the State's action.
See Bourne Pharmacy, 72 FR 18273, 18274 (2007).
Because Respondent's Colorado medical license has been
suspended, he is no longer currently authorized to dispense
controlled substances in Colorado, the State in which he seeks
registration. Thus, he no longer meets the CSA's requirement that he
be authorized to dispense controlled substances in the State where
he is registered. This conclusion provides a further reason to deny
his application.
---------------------------------------------------------------------------
Factors Two and Four--the Applicant's Experience in Dispensing
Controlled Substances and Compliance With State and Federal Laws
Related to Controlled Substances
The Government contends that the various Arizona Board Orders
establish that Respondent's experience in dispensing controlled
substances and his compliance with state and federal laws related to
controlled substances support the denial of his application and that
the Board's factual findings and legal conclusions are entitled to
preclusive effect in this proceeding. Req. for Final Agency Action, at
14-15. I agree in part.
Based on its findings that Respondent deviated from the standard of
care in his treatment of K.K. as well as at least 30 patients, to
include prescribing excessive controlled substances to chronic pain
patients, and that he ignored pharmacy inquiries and drug screenings in
patients who were clearly diverting, the Board restricted him from
prescribing or recommending controlled substances for two years.\22\
Id. at 4. Nonetheless, after the effective date of the Order,
Respondent continued to issue controlled substance prescriptions as
well order the administration of controlled substances to hospice
patients. These prescriptions and orders violated the CSA and DEA
regulations because he lacked the requisite state authority to dispense
controlled substances. 21 CFR 1306.03(a). See also Ariz. Rev. Stat.
Sec. 32-1854 (25). Moreover, Respondent issued at least 17 of these
prescriptions and orders for administration even after he surrendered
his registration. 21 U.S.C. 841(a)(1), 843(a)(3), 822(a)(2). Thus, by
itself, Respondent's unauthorized dispensing of controlled substances
while practicing in Arizona establishes that his registration would be
``inconsistent with the public interest.'' 21 U.S.C. 823(f).
---------------------------------------------------------------------------
\22\ While the Government argues that the Board's findings
establish that Respondent ``failed to comply with state law by
deviating from the standard of care in issuing prescriptions for
controlled substances,'' the Arizona Board did not find that he
engaged in ``[p]rescribing, dispensing, or administering controlled
substances . . . for other than therapeutic purposes.'' See Ariz.
Rev. Stat. Sec. 32-1854. In short, neither of the provisions the
Board found Respondent to have violated make specific reference to
controlled substances but are provisions generally applicable to all
osteopathic physicians. As such, while Respondent's conduct involved
controlled substances, the provisions he violated are not laws
related to controlled substances.
Notwithstanding that the Board did not find that he prescribed
``for other than therapeutic purposes,'' the Board's findings and
conclusions might well have supported an adverse finding under
Factor Two because ``DEA's authority to [deny an application] is not
limited to those instances in which a practitioner intentionally
diverts,'' and ``[a] practitioner who ignores the warning signs that
[his] patients are either personally abusing or diverting controlled
substances commits `acts inconsistent with the public interest,' 21
U.S.C. 824(a)(4), even if [he] is merely gullible or na[iuml]ve.''
Jayam Krishna-Iyer, 74 FR 459, 461 n.3 (2009) (citing Paul J.
Caragine, Jr., 63 FR 51592 (1998)). As Caragine explained, even
``[c]areless or negligent handling of controlled substances creates
the opportunity for diversion and [can] justify revocation or
denial'' of an application. 63 FR at 51601. The Government did not,
however, raise this theory in the Show Cause Order.
---------------------------------------------------------------------------
Moreover, there is additional evidence of prescribing violations
that supports this conclusion. As found above, upon moving to Colorado,
Respondent proceeded to issue numerous controlled substance
prescriptions without being registered in that State.
Under DEA's regulation, where a registrant seeks to change his
registered location, the registrant must apply to modify his
registration, 21 CFR Sec. 1301.51(a), and this regulation clearly
states that a ``request for modification shall be handled in the same
manner as an application for registration.'' Id. Sec. 1301.51(c).
Moreover, under 21 CFR 1301.13(a), ``[n]o person required to be
registered shall engage in any activity for which registration is
required until the application for registration is granted and a
Certificate of Registration is issued by the Administrator to such
person.'' Id.; see also Anthony E. Wicks, 78 FR 62676, 62678 (2013).
Thus, a registrant may ``not engage in any activity for which
registration is required until the application . . . is granted and a .
. . [r]egistration is issued.'' 21 CFR 1301.13(a). See also Mark Koch
79 FR 18714 (2014).
Here, the evidence shows that between July 29, 2014 and December 1,
2014, Respondent issued 89 prescriptions for controlled substances
while practicing in Grand Junction, Colorado, when he did not hold a
DEA registration in the State and was therefore not authorized to
dispense controlled substances in the State. 21 U.S.C. 822(e) (``A
separate registration shall be required at each principal place of
business or professional practice where the applicant . . . dispenses
controlled substances. . . .''); 21 CFR 1301.12. Moreover, while
Respondent claims that he was unaware that he could not issue
controlled substance prescriptions until the Agency approved his
modification request and that he stopped after he was told by the DI
that he could not write prescriptions until his request was approved,
the evidence shows that he issued further controlled substance
prescriptions after he was told by the DI that he lacked authority to
do so in Colorado.
Accordingly, I conclude that Respondent violated the CSA and DEA
regulations when he prescribed controlled substances in Colorado before
April 6, 2015. These findings, particularly when considered in light of
the extent of the Applicant's prescribing violations in Arizona,
support the conclusion that granting Applicant's application ``would be
inconsistent with the public interest.'' 21 U.S.C. 823(f).\23\
---------------------------------------------------------------------------
\23\ As for Factor Three, there is no evidence that Applicant
has been convicted of an offense ``relating to the manufacture,
distribution or dispensing of controlled substances.'' 21 U.S.C.
823(f)(3). There are, however, a number of reasons why a person who
has engaged in misconduct may never have been convicted of an
offense under this factor, let alone prosecuted for one. Dewey C.
MacKay, 75 FR 49956, 49973 (2010), pet. for rev. denied MacKay v.
DEA, 664 F.3d 808 (10th Cir. 2011). The Agency has therefore held
that ``the absence of such a conviction is of considerably less
consequence in the public interest inquiry'' and is therefore not
dispositive. Id.
As for the Government's arguments with respect to Factor Five,
I consider its contentions in my discussion of the appropriate
sanction.
---------------------------------------------------------------------------
SANCTION
Where, as here, the Government has established grounds to deny an
application, Respondent must then ``present[ ] sufficient mitigating
evidence'' to show why he can be entrusted with a new registration.
Samuel S. Jackson, 72 FR 23848, 23853 (2007) (quoting Leo R. Miller, 53
FR 21931, 21932 (1988)). `` `Moreover, because `past performance is the
best predictor of future performance,' ALRA Labs, Inc. v. DEA, 54 F.3d
450, 452 (7th Cir. 1995), [DEA] has repeatedly held that where [an
applicant] has committed acts inconsistent with the public interest,
the [applicant] must accept responsibility for [his] actions and
demonstrate that [he] will not engage in
[[Page 64948]]
future misconduct.'' Jayam Krishna-Iyer, 74 FR 459, 463 (2009) (citing
Medicine Shoppe, 73 FR 364, 387(2008)); see also Jackson, 72 FR at
23853; John H. Kennedy, 71 FR 35705, 35709 (2006); Cuong Tron Tran, 63
FR 64280, 64283 (1998); Prince George Daniels, 60 FR 62884, 62887
(1995).\24\
---------------------------------------------------------------------------
\24\ This rule also applies to other grounds that support the
denial of an application, such as where the Government has proven
that an applicant materially falsified his application. See Jackson,
72 FR, at 23853.
---------------------------------------------------------------------------
So too, an Applicant's candor during the course of an investigation
and subsequent proceeding is an important factor to be considered in
determining whether he has accepted responsibility for the proven
misconduct as well as the appropriate disposition of the matter. See
Robert F. Hunt, 75 FR 49995, 50004 (2010); Jeri Hassman, 75 FR 8194,
8236 (2010); see also Hoxie v. DEA, 419 F.3d 477, 483 (6th Cir. 2005)
(``Candor during DEA investigations, regardless of the severity of the
violations alleged, is considered by the DEA to be an important factor
when assessing whether a physician's registration is consistent with
the public interest.'').
While an applicant must accept responsibility for his misconduct
and demonstrate that he will not engage in future misconduct in order
to establish that its registration is consistent with the public
interest, DEA has repeatedly held that these are not the only factors
that are relevant in determining the appropriate disposition of the
matter. See, e.g., Joseph Gaudio, 74 FR 10083, 10094 (2009); Southwood
Pharmaceuticals, Inc., 72 FR 36487, 36504 (2007). Obviously, the
egregiousness and extent of an applicant's misconduct are significant
factors in determining the appropriate sanction. See Jacobo Dreszer, 76
FR 19386, 19387-88 (2011) (explaining that a respondent can ``argue
that even though the Government has made out a prima facie case, his
conduct was not so egregious as to warrant revocation''); Paul H.
Volkman, 73 FR 30630, 30644 (2008); see also Paul Weir Battershell, 76
FR 44359, 44369 (2011) (imposing six-month suspension, noting that the
evidence was not limited to security and recordkeeping violations found
at first inspection and ``manifested a disturbing pattern of
indifference on the part of [r]espondent to his obligations as a
registrant''); Gregory D. Owens, 74 FR 36751, 36757 n.22 (2009).
So too, the Agency can consider the need to deter similar acts,
both with respect to the respondent in a particular case and the
community of registrants. See Gaudio, 74 FR at 10095 (quoting
Southwood, 71 FR at 36503). Cf. McCarthy v. SEC, 406 F.3d 179, 188-89
(2d Cir. 2005) (upholding SEC's express adoption of ``deterrence, both
specific and general, as a component in analyzing the remedial efficacy
of sanctions'').
Having reviewed Respondent's Position Statement, I conclude that he
has failed to produce sufficient evidence to show why he should be
entrusted with a new registration. With respect to his acceptance of
responsibility, Respondent states only that he ``accepts full
responsibility for his actions that lead [sic] to the sanctions imposed
by Arizona'' and ``regrets and acknowledges that he prescribed
controlled substances in Colorado while his modification request was
pending.'' GX 5, at 7-8. Putting aside that the credibility of
Respondent's statement cannot be tested through cross-examination
because Respondent waived his right to a hearing, it is notable that
Respondent does not acknowledge that he materially falsified his March
2013 application for registration in Tennessee. Respondent's failure to
acknowledge his misconduct in this regard is fatal to his application.
Moreover, even with respect to his misconduct in prescribing
controlled substances in Colorado, I conclude that Respondent has not
adequately acknowledged his misconduct. Even putting aside that
ignorance of the law is no excuse, Respondent's statement regarding his
actions is less than forthcoming. As found above, Respondent asserted
that ``[a]s soon as I understood my mistake, I immediately stopped
prescribing controlled substances.'' Yet the evidence shows that on
December 1, 2014, the DI phoned him and told him that he lacked
authority to issue controlled substance prescriptions in Colorado.
While this should have been the point at which he ``understood [his]
mistake'' and ``immediately stopped prescribing,'' the evidence shows
that Respondent issued additional controlled substance prescriptions
thereafter. In short, Respondent's assertion is clearly false and I
therefore also find that he has not accepted responsibility for his
prescribing in Colorado when he lacked a DEA registration.
Likewise, while Respondent contends that he prescribed controlled
substances in violation of the first Arizona order because he ``did not
fully understand the scope of my initial restriction, which caused
[him] to inadvertently violate that restriction,'' having reviewed that
Order, I conclude that it was more than clear. See GX 8, at 4 (``IT IS
HEREBY FURTHER ORDERED that [Respondent], holder of osteopathic medical
License number 2686 is restricted from prescribing or recommending
Schedule I, II, III, or IV controlled substances for a period of two
(2) years from the effective date of this Order.''). Indeed, if
Respondent did not fully understand the scope of the restriction, he
had five weeks to contact the Board and clarify his understanding
before the Order went into effect. Nor is Respondent's explanation
credible given that he continued prescribing and issuing dispensing
orders even after he surrendered his DEA registration. I thus conclude
that Respondent has not credibly acknowledged his misconduct.
I also conclude that the record as a whole establishes that
Respondent's misconduct was egregious given his material falsification
of his March 2013 DEA application, his prescribing of controlled
substances after the Arizona Board's Order became effective, and his
continued prescribing in Arizona after he surrendered his DEA
registration. As for his prescribing in Colorado, even were I to accept
his excuse that he mistakenly believed that he could prescribe once he
submitted his request for modification, his issuance of prescriptions
after he was told by the DI that he lacked authority to write
prescriptions in the State renders this misconduct egregious as well.
Accordingly, I find that Respondent's misconduct warrants denial of
his application for this reason as well. So too, I find that the
Agency's interest in deterring similar misconduct by other applicants
who may contemplate materially falsifying their applications, as well
as by other registrants who may choose to ignore agency regulations and
prescribe when they lack authority to do so, supports the denial of his
application.
Of further note, as explained in my discussion of Factor One,
subsequent to the issuance of the Show Cause Order and Respondent's
submission of his Position Statement, the Colorado Medical Board
suspended his medical license and his license remains suspended as of
the date of this Order. As a consequence, Respondent no longer holds
authority under state law to dispense controlled substances in the
State where he is currently registered and thus no longer meets the
statutory prerequisite for obtaining and maintaining his registration.
See Frederick Marsh Blanton, 43 FR 27616, 27617 (1978) (``State
authorization to dispense or otherwise handle controlled substances is
a prerequisite to the issuance and maintenance of a Federal controlled
substances registration.''); see also 21 U.S.C. 823(f) (``The Attorney
General shall register practitioners . . .
[[Page 64949]]
if the applicant is authorized to dispense . . . controlled substances
under the laws of the State in which he practices.''); 21 U.S.C.
802(21) (``[t]he term `practitioner' means a physician . . . licensed,
registered, or otherwise permitted, by . . . the jurisdiction in which
he practices . . . to distribute, dispense, [or] administer . . . a
controlled substance in the course of professional practice'').\25\
---------------------------------------------------------------------------
\25\ See also Rezik A. Saqer, 81 FR 22122, 22125-27 (2016);
Sheran Arden Yeates, 71 FR 39130, 39131 (2006); Dominick A. Ricci,
58 FR 51104, 51105 (1993); Bobby Watts, 53 FR 11919, 11920 (1988).
---------------------------------------------------------------------------
While the Show Cause Order did not assert this as a ground for
denial of his application (because it occurred subsequent to the
issuance of the Order), the Government did serve a copy of its Addendum
which presented this development to me, on Respondent. In response to
this filing, Respondent has raised no objection.\26\ In any event,
there are two other independent and legally sufficient bases to deny
his application. Accordingly, I will deny his application.
---------------------------------------------------------------------------
\26\ DEA has previously held that ``[t]he rules governing DEA
hearings do not require the formality of amending a show cause order
to comply with the evidence. The Government's failure to file an
amended Show Cause Order alleging that Respondent's state CDS
license has expired does not render the proceeding fundamentally
unfair.'' Roy E. Berkowitz, 74 FR 36758, 36759-60 (2009); see also
Hatem M. Ataya, 81 FR 8221, 8245 (2016) (collecting cases).
---------------------------------------------------------------------------
ORDER
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 28
CFR 0.100(b), I order that the application of Richard J. Settles, for a
DEA Certificate of Registration as a practitioner be, and it hereby is,
denied. This Order is effective immediately.
Dated: September 13, 2016.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2016-22680 Filed 9-20-16; 8:45 am]
BILLING CODE 4410-09-P